

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11)



EP 1 177 792 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
06.02.2002 Bulletin 2002/06

(51) Int Cl.7: **A61K 31/505, A61P 25/30,
A61P 25/32, A61P 43/00**

(21) Application number: **01306163.5**

(22) Date of filing: **18.07.2001**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **27.07.2000 US 221268 P**

(71) Applicant: **Pfizer Products Inc.
Groton, Connecticut 06340 (US)**

(72) Inventors:
• **Fliri, Anton Franz Josef
Groton, Connecticut 06340 (US)**

• **Sanner, Mark Allen
Groton, Connecticut 06340 (US)**
• **Seymour, Patricia Ann
Groton, Connecticut 06340 (US)**
• **Zorn, Stevin Howard
Groton, Connecticut 06340 (US)**

(74) Representative: **Ruddock, Keith Stephen et al
Pfizer Limited, European Patent Department,
Ramsgate Road
Sandwich, Kent CT13 9NJ (GB)**

(54) **Dopamine D4 Ligands for the treatment of novelty-seeking disorders**

(57) The use of a dopamine D4 receptor ligand in the manufacture of a medicament for the treatment or prevention of a novelty-seeking disorder, particularly pathological gambling, attention deficit disorder with hy-

peractivity disorder, substance addiction, drug addiction, alcohol addiction and sex addiction.

EP 1 177 792 A2

Description

[0001] The present invention relates to a method of treating or preventing a novelty-seeking disorder selected from pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction, such as drug addiction and alcohol addiction, and sex addiction, using a dopamine D4 ligand. It also relates to a method of treating or preventing such disorders in mammals by administering a pyrido[1,2a]pyrazine derivative, benzimidazole derivative, bicyclic compound, spirocyclic benzo furan derivative, indole derivative or a related compound that is a dopamine D4 receptor ligand.


[0002] It has been determined that dopamine D4 receptors are related to various behavioral and personality disorders including novelty seeking disorders (See, e.g., Tarazi et al., *Mol. Psychiatry*, 4, 529-538(1999). The trait of novelty seeking was found to be related to dopaminergic activity in alcoholic men (Wiesbeck et al., *Psychoneuroendocrinology*, 20, 7(1999)). A large Finnish study provides support for an association between the D4 receptor gene (DRD4) and the behavioral trait of novelty seeking (Ekelund et al., *Am. J. Psychiatry*, 156, 1453-5 (1999)). Recent evidence has accumulated which supports a clinical linkage between attention deficit disorder with hyperactivity disorder, which has been associated with the novelty seeking trait, and dopamine receptor expression (see, e.g., Tarazi et al., *supra*; Anderson et al., *Neuroscience & Biobehavioral Rev.*, 24, 137-41 (2000)) and dopamine transporter gene expression (see, e.g., Dougherty et al., *The Lancet*, 354, 2132-2133 (1999)). Further evidence has been found for an association between the D4 gene and a susceptibility to pathological gambling (Comings, *CNS Spectr.*, 3, 20-37 (1998)) and a susceptibility to opioid addiction and substance abuse (Koller et al., *Mol. Psychiatry*, 2, 251-254 (1997)).

[0003] The following references refer, collectively, to pyrido[1,2a]pyrazine derivatives, benzimidazole derivatives, bicyclic compounds, spirocyclic benzofuran derivatives, indole derivatives or related compounds that exhibit activity as dopamine D4 receptor ligands: United States Patent No. 5,852,031, issued on December 22, 1998; United States Patent No. 5,883,094, issued on March 16, 1999; United States Patent No. 5,889,010, issued on March 30, 1999; PCT International Application PCT/IB97/00978, published as WO98/08835 on March 5, 1998; United States Patent Application No. 5,877,317 issued on March 2, 1999; United States Patent Application No. 5,021,420, issued on June 4, 1991; United States Patent Application No. 5,633,376, issued on May 27, 1997; United States Patent Application No. 5,432,177, issued on November 9, 1994; United States Patent Application No. 5,622,950, issued on April 22, 1997, PCT International Application No. PCT/EP93/01438, published as WO94/00458 on January 6, 1994; PCT International Application No. PCT/IB98/01198, published as WO99/09025 on February 25, 1999; United States Patent Application No. 5,998,414, issued on December 7, 1999; United States Patent Application No. 5,968,478, issued on October 19, 1999; United States Patent Application No. 6,040,448, issued on March 21, 2000; United States Patent Application No. 6,051,605, issued on April 18, 2000; United States Patent Application No. 5,945,421, issued on August 31, 1999; and United States Patent Application No. 5,798,350, issued on August 25, 1998. All of the foregoing PCT International Applications designate the United States. The foregoing patents and patent applications are incorporated by reference in their entirety.

Summary of the Invention

[0004] This invention relates to a method of treating or preventing a novelty-seeking disorder selected from pathological gambling, attention deficit disorder with hyperactivity disorder (ADHD), substance addiction (e.g., drug addiction and alcohol addiction) and sex addiction in a subject, including a human, comprising administering to the subject an effective amount of:

(a) a compound of formula I:



wherein Ar is phenyl, naphthyl, benzoxazolonyl, indolyl, indolonyl, benzimidazolyl, quinolyl, furyl, benzofuryl, thiienyl, benzothienyl, oxazolyl, or benzoxazolyl;

Ar¹ is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzisoxazolyl, or benzisothiazolyl; A is O, S, SO, SO₂, C=O, CHO, or -(CR³R⁴)-; n is 0, 1 or 2; each of Ar and Ar¹ may be independently and optionally substituted with one to four substituents independently selected from the group consisting of fluoro, chloro, bromo, iodo, cyano, nitro, thiociano, -SR, -SOR, -SO₂R, -NHSO₂R, -(C₁-C₆)alkoxy, -NR¹R², -NRCOR¹, -CONR¹R², Ph, -COR, COOR, -(C₁-C₆)alkyl, -(C₁-C₆)alkyl substituted with one to six halogens, -(C₃-C₆)cycloalkyl, and trifluoromethoxy;

each and every R, R¹, and R² is independently selected from the group consisting of hydrogen, -(C₁-C₆)alkyl, -(C₁-C₆)alkyl substituted with one to thirteen halogens selected from fluorine, chlorine, bromine and iodine, phenyl, benzyl, -(C₂-C₆)alkenyl, -(C₃-C₆)cycloalkyl, and -(C₁-C₆)alkoxy;


each and every R³ and R⁴ is independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, or i-propyl; diastereomeric and optical isomers thereof; and pharmaceutically acceptable salts thereof;

(b) a compound of formula II:

II:

15

20



25

wherein X¹, X² and X³ are independently selected from carbon and nitrogen;

R⁰, R¹ and R² are independently selected from hydrogen, halo (e.g., chloro, fluoro, bromo or iodo), (C₁-C₆)alkyl optionally substituted with from one to three fluorine atoms and (C₁-C₆)alkoxy optionally substituted with from one to three fluorine atoms;

30

R³ is hydrogen, (C₁-C₆)alkyl or benzyl, wherein the phenyl moiety of said benzyl group may optionally be substituted with from one or more substituents, preferably with from zero to three substituents, independently selected from halo (e.g., chloro, fluoro, bromo or iodo), cyano, (C₁-C₆)alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₆)alkoxy optionally substituted with from one to three fluorine atoms, (C₁-C₆)alkylsulfonyl, (C₁-C₆)alkylamino, amino, di-(C₁-C₆)alkylamino and (C₁-C₆)carboxamido;

35

R⁴, R⁵ and R⁶ are independently selected from hydrogen, halo (e.g., chloro, fluoro, bromo or iodo), cyano, (C₁-C₆)alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₆)alkoxy optionally substituted with from one to three fluorine atoms, (C₁-C₆)alkylsulfonyl, (C₁-C₆)acylamino, (phenyl)[(C₁-C₆)acyl]amino, amino, (C₁-C₆)alkylamino and di-(C₁-C₆)alkylamino;

40


with the proviso that when X³ is nitrogen, R² is absent;

(c) a compound of formula III:

45

50

55



wherein each of the dotted lines represents an optional double bond;

20 X is carbon or nitrogen;

R¹ is benzyl, aryl selected from phenyl, indanyl and naphthyl, or heteroaryl selected from pyridyl, thienyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, quinolyl and imidazolyl, wherein each of the foregoing aryl, heteroaryl and (C₁-C₄)alkyl groups, and the phenyl moiety of the benzyl group, may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from halo (e.g., chloro, fluoro, bromo or iodo), (C₁-C₆)alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₆)alkoxy optionally substituted with from one to three fluorine atoms, cyano, -C(=O)R⁸, aryl and heteroaryl, wherein said aryl is selected from phenyl, indanyl and naphthyl and said heteroaryl is selected from pyridyl, thienyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, quinolyl and imidazolyl;.

25 R² and R³ are independently selected from hydrogen, hydroxy, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, cyano, -CONH₂ and -NHC(=O)R⁹, or R² and R³ together form an oxo group;

30 R⁴ is hydrogen, sulfur, oxygen, (C₁-C₆)alkyl, amino, -NHR¹⁰, -SR¹⁰, OR¹⁰ or hydroxy;

35 R⁵, R⁶ and R⁷ are independently selected from hydrogen, halo (e.g., chloro, fluoro, bromo or iodo), cyano, (C₁-C₆)alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₆)alkoxy optionally substituted with from one to three fluorine atoms, (C₁-C₆)alkylsulfonyl, (C₁-C₆)acylamino, (phenyl)[(C₁-C₆)acyl]amino, amino, (C₁-C₆)alkylamino, di-(C₁-C₆)alkylamino, aryl and heteroaryl, wherein said aryl is selected from phenyl, naphthyl and indanyl, and said heteroaryl is selected from pyridyl, thienyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, quinolyl and imidazolyl;


40 R⁸, R⁹ and R¹⁰ are independently selected from hydrogen and (C₁-C₆)alkyl; and

45 R¹¹ is hydrogen, (C₁-C₆)alkyl or benzyl, wherein the phenyl moiety of said benzyl may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from halo (e.g., fluoro, chloro, bromo, or iodo), (C₁-C₆)alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₆)alkoxy optionally substituted with from one to three fluorine atoms, amino, cyano, (C₁-C₆)alkylamino and di-(C₁-C₆)alkylamino;

50 with the proviso that: (a) R⁴ can not be either oxygen or hydroxy when both R² and R³ are hydrogen; (b) when the five membered ring of formula I contains a double bond, R¹¹ is absent; (c) when R⁴ is sulfur or oxygen, R⁴ is double bonded to the carbon to which is attached and such carbon is single bonded to both adjacent ring nitrogen atoms; and (d) when X is nitrogen and is double bonded to an adjacent carbon, R¹ is absent;

(d) a compound of formula IV:

55



(IV)

and to pharmaceutically acceptable salts and solvates thereof wherein:

15 the dashed line in the above formula represents an optional double bond where X^2 is not O;
 X^1 and X^2 are each independently selected from O and $-(CH_2)_j$ - wherein j is 1 or 2;
 X^3 is $-CH(R^5)N(R^8)CH(R^6)$ -, $-CH(R^5)C(R^8)(R^9)CH(R^6)$ -, $-C(R^5)=C(R^8)CH(R^6)$ -, or $-CH(R^5)C(R^8)=C(R^6)$;-
 R^1 and R^2 are each independently H, hydroxy, or C_1-C_6 alkyl;
 R^1 and R^2 are taken together as a bond;

20 each R^3 is independently selected from $-S(O)_jR^7$ wherein j is an integer ranging from 0 to 2, $-C(O)R^7$, $-OR^7$,
 $-NC(O)R^7$, $-NR^7R^{12}$, and the substituents provided in the definition of R^7 other than H;
 R^4 is absent where the dashed line in the above formula 1 represents a double bond or R^4 is selected from
 H and the substituents provided in the definition of R^3 ;

25 or R^3 and R^4 are taken together with the carbon atom to which each is attached to form a 5-10 membered
mono-cyclic or bicyclic group wherein said cyclic group may be carbocyclic or heterocyclic with 1 to 3 heteroatoms selected from O, S, and $-N(R^{11})$ - with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; said cyclic group is saturated or partially unsaturated; aromatic or non-aromatic; 1 or 2 of the carbon atoms in said cyclic group optionally may be replaced by an oxo $-C(O)$ - moiety; and said cyclic group is optionally substituted by 1 to 3 R^{10} groups;

30 R^5 and R^6 are each independently selected from H and C_1-C_4 alkyl;
or R^5 and R^6 are taken together as $-(CH_2)_q$ - wherein q is 2 or 3;
or R^5 or R^6 is taken together with R^8 as defined below;

35 each R^7 is independently selected from H, $-(CH_2)_t(C_6-C_{10}$ aryl) and $-(CH_2)_t(4-10$ membered heterocyclic), wherein t is an integer ranging from 0 to 5; 1 or 2 of the carbon atoms of said heterocyclic group optionally may be replaced with an oxo $-C(O)$ - group; said aryl and heterocyclic R^7 groups are optionally fused to a benzene ring, a C_5-C_8 saturated cyclic group, or a 4-10 membered heterocyclic group; the $-(CH_2)_t$ - moieties of the foregoing R^7 groups optionally include a carbon-carbon double or triple bond where t is an integer between 2 and 5; and the foregoing R^7 groups, except H, are optionally substituted by 1 to 5 R^{10} groups;

40 R^8 is selected from the substituents provided in the definition of R^7 other than H;
 R^9 is selected from the substituents provided in the definition of R^7 ;
or R^8 and R^9 are taken together with the carbon to which each is attached to form a 5-10 membered mono-cyclic or bicyclic group wherein said cyclic group is carbocyclic or heterocyclic with 1 to 3 heteroatoms selected from O, S, and $-N(R^{11})$ - with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; saturated or partially unsaturated; aromatic or non-aromatic; 1 or 2 of the carbon atoms in said cyclic group optionally may be replaced by an oxo $-C(O)$ - moiety; and said cyclic group is optionally substituted by 1 to 3 R^{10} groups;

45 or R^8 taken together with either R^5 or R^6 and the separate carbon atoms to which each is attached to form a fused 5-10 membered mono-cyclic or bicyclic group wherein said cyclic group may be carbocyclic or heterocyclic with 1 to 3 heteroatoms selected from O, S, and $-N(R^{11})$ - with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; saturated or partially unsaturated; aromatic or non-aromatic; 1 or 2 of the carbon atoms in said cyclic group optionally may be replaced by an oxo $-C(O)$ - moiety; and said cyclic group is optionally substituted by 1 to 3 R^{10} groups;


50 each R^{10} is independently selected from C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-OR^{11}$, $-C(O)R^{11}$, $-C(O)OR^{11}$, $-NR^{12}C(O)OR^{11}$, $-OC(O)R^{11}$,
 $-NR^{12}SO_2R^{11}$, $-SO_2NR^{11}R^{12}$, $-NR^{12}C(O)R^{11}$, $-C(O)NR^{11}R^{12}$, $-NR^{11}R^{12}$, $-S(O)_j(C_1-C_6$ alkyl) wherein j is an integer ranging from 0 to 2, $-(CH_2)_m(C_6-C_{10}$ aryl), $-SO_2(CH_2)_m(C_6-C_{10}$ aryl), $-S(CH_2)_m(C_6-C_{10}$ aryl), $-O(CH_2)_m(C_6-C_{10}$ aryl) and $-(CH_2)_m(4-10$ membered heterocyclic), wherein m is an integer ranging from 0 to 4; said

⁵ C₁-C₁₀ alkyl group optionally contains 1 or 2 hetero moieties selected from O, S and -N(R¹²)- with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; said aryl and heterocyclic R¹⁰ groups are optionally fused to a C₆-C₁₀ aryl group, a C₅-C₈ saturated cyclic group, or a 4-10 membered heterocyclic group; and said alkyl, aryl and heterocyclic R¹⁰ groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -NR¹²SO₂R¹¹, -SO₂NR¹¹R¹², -C(O)R¹¹, -C(O)OR¹¹, -OC(O)R¹¹, -NR¹²C(O)R¹¹, -C(O)NR¹¹R¹², -NR¹¹R¹², C₁-C₆ alkyl, -OR¹¹ and the substituents listed in the definition of R¹¹;

¹⁰ each R¹¹ is independently selected from H, C₁-C₁₀ alkyl, -(CH₂)_m(C₆-C₁₀ aryl), and -(CH₂)_m(4-10 membered heterocyclic), wherein m is an integer ranging from 0 to 4; said alkyl group optionally includes 1 or 2 hetero moieties selected from O, S and -N(R¹²)- with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; said aryl and heterocyclic R¹¹ groups are optionally fused to a C₆-C₁₀ aryl group, a C₅-C₈ saturated cyclic group, or a 4-10 membered heterocyclic group; and the foregoing R¹¹ substituents, except H, are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -C(O)R¹², -C(O)OR¹², -CO(O)R¹², -NR¹²C(O)R¹³, -C(O)NR¹²R¹³, -NR¹²R¹³, hydroxy, C₁-C₆ alkyl, and C₁-C₆ alkoxy; and,

¹⁵ each R¹² and R¹³ is independently H or C₁-C₆ alkyl;


(e) a compound of formula V:



or the pharmaceutically acceptable salt thereof, wherein the broken line represents an optional double bond;

³⁵ a is 0 or 1, wherein when a is 0, X may form an optional double bond with the carbon adjacent to V;
V is CHR¹⁰ wherein R¹⁰ is hydrogen or (C₁-C₆)alkyl;
T is nitrogen or CH;
X is nitrogen or CR¹¹ wherein R¹¹ is hydrogen, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, hydroxy or cyano;
⁴⁰ Y and Z are each independently nitrogen or CR¹² wherein R¹² is hydrogen, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano, (C₁-C₆)alkoxy or (C₁-C₆)alkyl;
R¹ is hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano or (C₁-C₆)alkyl;
R², R⁶, R⁷, R⁸ and R⁹ are each independently selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano, (C₁-C₆)alkoxy and (C₁-C₆)alkyl;
⁴⁵ R³ and R⁴ are each independently hydrogen or (C₁-C₆)alkyl; and
R⁵ is hydrogen, (C₁-C₆)alkoxy, trifluoromethyl, cyano, (C₁-C₆)alkyl or R¹³CO- wherein R¹³ is amino, (C₁-C₆)alkylamino, ((C₁-C₆)alkyl)₂amino, (C₁-C₆)alkyl, (C₆-C₁₀)aryl;

⁵⁰ or when a is 1, R¹ and R¹⁰ may be taken together with the carbons to which they are attached to form a compound of the formula



wherein the broken lines represent optional bonds;

15 T, X, Y, Z, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ are defined as above;

b is 0 or 1; and


A and B are each independently CH, CH₂, oxygen, sulfur, NH or nitrogen;

20 with the proviso that when X is nitrogen, the optional double bond between X and V does not exist;

with the proviso that when b is 0, the optional double bond between A and B does not exist; and

with the proviso that when b is 1, A and B cannot both be oxygen or sulfur;

or (f) a compound of formula VI:



35 wherein a is oxygen, CH₂, C(CH₃)₂, NR¹⁰, sulfur, SO or SO₂;

b is oxygen, CH₂, C=O, C=NR¹¹, C=NOH, SO₂, sulfur, SO, C=NO(C₁-C₅)alkyl or CR⁷R⁸;

each of R¹ through R⁸ is selected, independently, from hydrogen, halogen (e.g., chloro, fluoro, bromo or iodo),

40 trifluoromethyl, cyano and hydroxy, or R⁷ and R⁸ together can be C(=O)NH₂ or C(=O)N(C₁-C₄)alkyl, with the proviso that neither R⁷ nor R⁸ can be halo when a is oxygen, NR¹¹, sulfur, SO or SO₂; and

each of R¹⁰ and R¹¹ is selected, independently, from hydrogen, benzyl and (C₁-C₆)alkyl;

and the pharmaceutically acceptable salts of such compounds.

[0005] The term "one or more substituents", as used herein, includes from one to the maximum number of substituents possible based on the number of available bonding sites.

[0006] The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof.

[0007] The term "alkoxy", as used herein, unless otherwise indicated, refers to radicals having the formula -O-alkyl, wherein "alkyl" is defined as above.

50 [0008] In one embodiment this invention relates to a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of a compound of formula I wherein

[0009] Ar is phenyl, naphthyl, benzoxazolonyl, indolyl, indolonyl, benzimidazolyl, or quinolyl; Ar¹ is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, or benzisoxazolyl; A is O, S, SO₂, C=O, CHO, or CH₂; n is 0 or 1, wherein Ar and Ar¹ may be independently substituted with up to three substituents independently selected from the group consisting of fluoro, chloro, cyano, -NR¹R², -(C₁-C₆)alkoxy, -COOR, -CONR¹R², and -(C₁-C₆)alkyl and the pharmaceutically acceptable salts thereof.

Embodiments of Formula I

[0010] In certain embodiments, this invention relates to a method of treating or preventing a novelty-seeking, comprising administering to the subject an effective amount of a compound of formula I wherein A is O or S; n is 1; Ar is phenyl or substituted phenyl, and the pharmaceutically acceptable salts thereof.

[0011] In other embodiments, this invention relates to a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of a compound of formula I wherein A is CH₂; n is 0; Ar is benzoxazolonyl or substituted benzoxazolonyl; and the pharmaceutically acceptable salts thereof.; or wherein A is CH₂; n is 0; Ar is indolyl or substituted indolyl; and the pharmaceutically acceptable salts thereof; or wherein A is C=O or CHO; n is 0 or 1; Ar is phenyl or substituted phenyl; and the pharmaceutically acceptable salt thereof; or wherein A is O; Ar is fluorophenyl, difluorophenyl or cyanophenyl; Ar¹ is chloropyridinyl; and the pharmaceutically acceptable salt thereof; or wherein A is O; Ar is fluorophenyl, difluorophenyl or cyanophenyl; Ar¹ is fluoropyrimidinyl; and the pharmaceutically acceptable salt thereof; or wherein A is O; Ar is fluorophenyl, difluorophenyl or cyanophenyl; Ar¹ is fluorophenyl; and the pharmaceutically acceptable salt thereof; or wherein Ar¹ is 5-chloro-pyridin-2-yl; and the pharmaceutically acceptable salt thereof; or wherein Ar¹ is 5-fluoro-pyrimidin-2-yl; and the pharmaceutically acceptable salts thereof.

[0012] In preferred embodiments of the method, A is O; S, SO, or SO₂; C=O or CHO; CH₂; phenyl or substituted phenyl;

[0013] In other preferred embodiments of the method, Ar is naphthyl or substituted naphthyl; benzoxazolonyl or substituted benzoxazolonyl; indolyl or substituted indolyl; indolonyl or substituted indolonyl; benzimidazolyl or substituted benzimidazolyl; quinolyl or substituted quinolyl.

[0014] In other preferred embodiments of the method, Ar¹ is phenyl or substituted phenyl; pyridinyl or substituted pyridinyl; pyridazinyl or substituted pyridazinyl; pyrimidinyl or substituted pyrimidinyl; pyrazinyl or substituted pyrazinyl; benzisoxazolyl or substituted benzisoxazolyl.

[0015] Specific preferred embodiments of the invention relate to a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of the following compounds:

(7R,9aS)-7-(4-fluorophenoxy)methyl-2-(5-chloro-pyridin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7R,9aS)-7-(3,5-difluorophenoxy)methyl-2-(5-chloro-pyridin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

3-[[(7R,9aS)-2-(5-chloro-pyridin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazin-7-ylmethyl]-3H-benzoxazol-2-one];

3-[[(7R,9aS)-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazin-7-ylmethyl]-3H-benzoxazol-2-one];

(7R,9aS)-7-(4-fluorophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7R,9aS)-7-(3,5-difluorophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7R,9aS)-7-(3,4-difluorophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7R,9aS)-7-(3-cyanophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7R,9aS)-7-(4-cyanophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7R,9aS)-7-(4-iodophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7R,9aS)-7-(4-fluorophenoxy)methyl-2-(4-fluorophenyl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7S,9aS)-7-(4-fluorophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7S,9aS)-7-(2-carbomethoxy-4-fluorophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7S,9aS)-7-(2-bromo-4-fluorophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7S,9aS)-7-(4-fluoro-2-trifluoromethylphenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7S,9aS)-7-(3,5-difluorophenoxy)methyl-2-(5-chloro-pyridin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7S,9aS)-7-(4-fluorophenoxy)methyl-2-(5-chloro-pyridin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1*H*-pyrido[1,2-a]pyrazine;
 (7S,9aS)-7-(2-chlorophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1*H*-pyrido[1,2-a]pyrazine;
 (7S,9aS)-7-(4-fluoro-2-methylphenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1*H*-pyrido[1,2-a]pyrazine;
 (7S,9aS)-7-(2,4-difluorophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1*H*-pyrido[1,2-a]pyrazine; and the pharmaceutically acceptable salt thereof.

10 Embodiments of Formula II

[0016] In preferred embodiments of the invention, compounds used in the practice of the invention include those of the formula II, wherein R¹ is bromine and X² is nitrogen; or wherein R¹ is chlorine and X² is nitrogen.

[0017] Examples of specific compounds based on formula II used in this invention include the following:

1-3-[3-(4-pyridin-2-yl-piperazin-1-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one;
 1-[3-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propyl]-1,3-dihydro-benzoimidazol-2-one;
 1-[3-[4-(5-chloro-pyridin-2-yl)-piperazin-1-yl]-propyl]-1,3-dihydro-benzoimidazol-2-one;
 1-[3-[4-(5-bromo-pyridin-2-yl)-piperazin-1-yl]-propyl]-1,3-dihydro-benzoimidazol-2-one;
 1-[3-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one; and
 1-[3-[4-(6-chloro-pyridazin-3-yl)-piperazin-1-yl]-propyl]-1,3-dihydro-benzoimidazol-2-one.

[0018] Other embodiments of this invention include methods using compounds of the formula II wherein X² is carbon, X³ is nitrogen and R¹ is hydrogen or substituted or unsubstituted alkoxy; or wherein X² and X³ are both carbon and R¹ is hydrogen or substituted or unsubstituted alkoxy; or wherein X¹ is carbon; or wherein X² and X³ are both carbon and each of R⁰, R¹ and R² is other than a fluoroalkyl group; or wherein X¹ is nitrogen.

[0019] Other embodiments of this invention include use of the following compounds of formula II:

1-[2-cyano-3-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one;
 1-[5-methyl,3-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one;
 1-[6-cyano,3-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one;
 1-[3-[4-(5-fluoro-pyridin-2-yl)-propyl]-3-methyl-1,3-methyl-1,3-dihydro-benzoimidazol-2-one;
 1-[3-[4-(3-cyano-pyridin-2-yl)-piperazin-1-yl]-propyl]-1,3-dihydro-benzoimidazol-2-one;
 1-[3-[4-(4-cyano-pyridin-2-yl)-piperazin-1-yl]-propyl]-1,3-dihydro-benzoimidazol-2-one;
 1-[3-[4-(6-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propyl]-1,3-dihydro-benzoimidazol-2-one;
 1-[3-[4-(5-fluoro-pyridin-2-yl)-piperazin-1-yl]-propyl]-5-fluoro-1,3-dihydro-benzoimidazol-2-one; and
 1-[3-[4-(5,fluoro-pyridin-2-yl)-piperazin-1-yl]-propyl]-5,6-difluoro-1,3-dihydro-benzoimidazol-2-one.

[0020] Preferred embodiments of the invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of any of the following compounds:

1-Benzimidazol-1-yl-3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propan-2-ol;
 1-(5-Chloro-benzimidazol-1-yl)-3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propan-2-ol;
 1-[3-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-propyl]-5-trifluoromethyl-1*H*-benzoimidazole;
 1-[3-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-propyl]-1*H*-benzoimidazole;
 1-[3-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-propyl]-3-methyl-1,3-dihydro-benzoimidazol-2-one;
 1-Benzimidazol-1-yl-3-(4-o-tolyl-piperazine-1-yl)-propan-2-ol;
 1-Benzimidazol-1-yl-3-(4-m-tolyl-piperazine-1-yl)-propan-2-ol;
 1-Benzimidazol-1-yl-3-(4-p-tolyl-piperazin-1-yl)-propan-2-ol;
 1-Benzimidazol-1-yl-3-[4-(4-chloro-phenyl)-phenyl-methyl]-piperazin-1-yl]-propan-2-ol;
 1-Benzimidazol-1-yl-3-[4-(2-chloro-phenyl)-piperazin-1-yl]-propan-2-ol;
 1-Benzimidazol-1-yl-3-[4-(4-chloro-phenyl)-piperazin-1-yl]-propan-2-ol;
 1-Benzimidazol-1-yl-3-[4-(3-chloro-phenyl)-piperazin-1-yl]-propan-2-ol;
 1-Benzimidazol-1-yl-3-[4-(3-chloro-phenyl)-piperazin-1-yl]-propan-2-ol;
 1-Benzimidazol-1-yl-3-(4-pyrimidin-2-yl-piperazin-1-yl)-propan-2-ol;
 1-Benzimidazol-1-yl-3-(4-naphthalen-1-yl-piperazin-1-yl)-propan-2-ol;
 1-Benzimidazol-1-yl-3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-propan-2-ol;
 1-Benzimidazol-1-yl-3-(4-benzyl-piperazin-1-yl)-propan-2-ol;

1-Benzoimidazol-1-yl-3-[4-(2-trifluoromethyl-benzyl)-piperazin-1-yl]-propan-2-ol;
 1-Benzoimidazol-1-yl-3-[4-(2-ethoxy-benzyl)-piperazin-1-yl]-propan-2-ol;
 1-Benzoimidazol-1-yl-3-{4-[3-(3-trifluoromethyl-phenyl)-propyl]-piperazin-1-yl}-propan-2-ol; and
 1-Benzoimidazol-1-yl-3-{4-[2-(3-trifluoromethyl-phenyl)-ethyl]-piperazin-1-yl}-propan-2-ol;

5

[0021] Other preferred embodiments of the invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of any of the following compounds of formula II:

(4-Chloro-2-nitro-phenyl)-{3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propyl}-amine;
 {3-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-propyl}-{2-nitro-4-trifluoromethyl-phenyl}-amine;
 4-Chloro-N1-{3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propyl}-benzene-1,2-diamine;
 1-(4,5-Dichloro-2-nitro-phenylamino)-3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propan-2-ol;
 1-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-3-(2-phenyl-benzoimidazol-1-yl)-propan-2-ol;
 1-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-3-(2-propyl-benzoimidazol-1-yl)-propan-2-ol;
 1-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-3-(2-methyl-benzoimidazol-1-yl)-propan-2-ol;
 5-Fluoro-1-(3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propyl)-2-methyl-1H-benzoimidazole;
 5-Chloro-1-(3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-2-hydroxy-propyl)-1,3-dihydro-benzoimidazol-2-one;
 5-Fluoro-1-(3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-2-hydroxy-propyl)-1,3-dihydro-benzoimidazol-2-one;
 1-Benzoimidazol-1-yl-3-[4-(3-methoxy-phenyl)-piperazin-1-yl]-propan-2-ol;
 1-Benzoimidazol-1-yl-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propan-2-ol;
 1-Benzoimidazol-1-yl-3-(4-phenyl-piperazin-1-yl)-propan-2-ol;
 1-[4-[4-(3-Benzimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-phenyl]-ethanone;
 1-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-3-benzoimidazol-1-yl-propan-2-ol;
 1-Benzoimidazol-1-yl-3-[4-(3,4-dimethyl-phenyl)-piperazin-1-yl]-propan-2-ol;
 4-[4-(3-Benzimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-phenol;
 1-Benzoimidazol-1-yl-3-(4-phenethyl-piperazin-1-yl)-propan-2-ol;
 1-Benzoimidazol-1-yl-3-[4-(3-phenyl-allyl)-piperazin-1-yl]-propan-2-ol;
 1-Benzoimidazol-1-yl-3-[4-(3-chloro-propyl)-piperazin-1-yl]-propan-2-ol;
 2-[4-(3-Benzimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-1-morpholin-4-yl-ethanone;
 1-(4-Benzhydryl-piperazin-1-yl)-3-benzoimidazol-1-yl-propan-2-ol;
 1-Benzoimidazol-1-yl-3-[4-[bis-(4-fluoro-phenyl)-methyl]-piperazin-1-yl]-propan-2-ol;
 1-Benzoimidazol-1-yl-3-[4-(4-nitro-phenyl)-piperazin-1-yl]-propan-2-ol;
 4-(3-Benzimidazol-1-yl-2-hydroxy-propyl)-piperazine-1-carboxylic;
 5-Fluoro-1-[3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propyl]-1H-benzoimidazole;
 3-[4-(3-Benzimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-1-phenyl-propan-1-one;
 4-[4-(3-Benzimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one;
 1-Benzoimidazol-1-yl-3-[4-(tetrahydro-furan-2-yl)methyl]-piperazin-1-yl]-propan-2-ol;
 [4-(3-Benzimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-[tetrahydro-furan-2-yl]-methanone;
 [4-(3-Benzimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-[2,3-dihydro-benzo[1,4]dioxin-2-yl]-methanone;
 [4-(3-Benzimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-[tetrahydro-furan-2-yl]-methanone;
 [[4-(3-Benzimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-2,3-dihydro-benzo[1,4]dioxin-2-yl]-methanone;
 1-Benzoimidazol-1-yl-3-[4-(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-piperazin-1-yl]-propan-2-ol;
 1-Benzoimidazol-1-yl-3-[4-(2-nitro-butyl)-piperazin-1-yl]-propan-2-ol;
 3-[4-(3-Benzimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-1-(4-chloro-phenyl)-propan-1-one;
 1-Benzoimidazol-1-yl-3-[4-(5,5-diphenyl-pent-3-phenyl)-piperazin-1-yl]-propan-2-ol;
 1-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-3-(2-phenyl-benzoimidazol-1-yl)-propan-2-ol;
 5,6-Difluoro-1-(3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propyl)-1H-benzoimidazol; and
 1-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-3-(2-propyl-benzoimidazol-1-yl)-propan-2-ol.

50 Embodiments of Formula III

[0022] Other embodiments of this invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of any of the following compounds:

- 55 (a) compounds of formula III wherein R¹ is phenyl and is either unsubstituted or substituted with one or two substituents selected from halo, (C₁-C₆)alkyl substituted with from one to three fluorine atoms, (C₁-C₆)alkoxy substituted with from one to three fluorine atoms, cyano, -C(=O)R⁸, aryl and heteroaryl;
 (b) compounds of formula III wherein R¹ is indanyl and is either unsubstituted or substituted with one or two sub-

stituents selected from halo, (C_1 - C_6)alkyl substituted with from one to three fluorine atoms, (C_1 - C_6)alkoxy substituted with from one to three fluorine atoms, cyano, - $C(=O)R^8$, aryl and heteroaryl;

(c) compounds of formula III wherein R^1 is naphthyl and is either unsubstituted or substituted with one or two substituents selected from halo, (C_1 - C_6)alkyl substituted with from one to three fluorine atoms, (C_1 - C_6)alkoxy substituted with from one to three fluorine atoms, cyano, - $C(=O)R^8$, aryl and heteroaryl;

(d) compounds of formula III wherein R^1 is heteroaryl and is either unsubstituted or substituted with one or two substituents selected from halo, (C_1 - C_6)alkyl substituted with from one to three fluorine atoms, (C_1 - C_6)alkoxy substituted with from one to three fluorine atoms, cyano, - $C(=O)R^8$, aryl and heteroaryl;

(e) compounds of formula III wherein R^5 ; R^6 and R^7 are independently selected from (C_1 - C_6)alkyl optionally substituted with from one to three fluorine atoms, (C_1 - C_6)alkoxy optionally substituted with from one to three fluorine atoms, cyano and halo;

(f) compounds of formula III wherein R^4 is hydrogen;

(g) compounds of formula III wherein R^4 is (C_1 - C_6)alkyl;

(h) compounds of formula III wherein R^4 is amino;

(i) compounds of formula III wherein R^4 is - NHR^{10} ;

(j) compounds of formula III wherein R^4 is SR^{10} ;

(k) compounds of formula III wherein R^4 is - OR^{10} ;

(l) compounds of formula III wherein R^4 is hydroxy;

(m) compounds of formula III wherein R^{11} is absent;

(n) compounds of formula III wherein R^2 and R^3 are both hydrogen;

(o) compounds of formula III wherein one or both of R^2 and R^3 are hydroxy;

(p) compounds of formula III wherein R^2 and R^3 together form an oxo group;

(q) compounds of formula III wherein one of R^2 and R^3 is (C_1 - C_6)alkyl;

(r) compounds of formula III wherein X is carbon;


(s) compounds of formula III wherein X is nitrogen;

(t) compounds of formula III wherein R^4 is oxygen; and


(v) compounds of formula III wherein R^4 is sulfur.

Emodiments of Formula IV

[0023] Certain embodiments of the invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of compounds of formula IV having the following structure




wherein R^3 is $-(CH_2)_t(C_6-C_{10}$ aryl) or $-(CH_2)_t(4-10$ membered heterocyclic), R^4 is H or hydroxy, and R^8 is $-(CH_2)_t(C_6-C_{10}$ aryl) or $-(CH_2)_t(4-10$ membered heterocyclic), t is an integer ranging from 0 to 5, and the foregoing R^3 and R^8 heterocyclic groups are optionally fused to a benzene ring, and said R^3 and R^8 groups are optionally substituted by 1 to 3 R^{10} groups. More specific embodiments include use of those compounds wherein R^8 and R^3 are each independently selected from phenyl and pyrimidyl, optionally substituted by 1 to 3 substituents independently selected from halo, cyano, methoxy, trifluoromethyl, methanesulfonyl, amino, trifluoromethoxy, acetamido, and C_1 - C_6 alkyl. Other more specific embodiments include those wherein R^3 is a heterocyclic group fused to a benzene ring and, optionally, 1 or 2 of the carbon atoms of said heterocyclic group is replaced with an oxo - $C(O)$ - group. In particular, such specific embodiments of the invention use compounds wherein R^3 comprises the following groups:



and

5

10




15

wherein the benzo portion of the above R³ groups is optionally substituted by 1 to 3 R¹⁰ groups.

[0024] Other embodiments of the invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of any compound of formula IV having the following structure

20




25

wherein R³ is -O(CH₂)_t(C₆-C₁₀ aryl) or -O(CH₂)_t(4-10 membered heterocyclic), R⁴ is H or hydroxy, and R⁸ is -(CH₂)_t(C₆-C₁₀ aryl) or -(CH₂)_t(4-10 membered heterocyclic), wherein t is an integer ranging from 0 to 5, and wherein the foregoing R³ and R⁸ groups are optionally substituted by 1 to 3 R¹⁰ groups. More specific embodiments of the invention include the described method wherein R³ is phenoxy and R⁸ is phenyl or pyrimidyl, and said R³ and R⁸ groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, methoxy, trifluoromethyl, methanesulfonyl, amino, trifluoromethoxy, acetamido, and C₁-C₆ alkyl.

30

[0025] Other embodiments of the invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of any compound of formula IV having the following structure

35



40


wherein R³ and R⁴ are taken together with the carbon atom to which each is attached to form a 5-10 membered monocyclic or bicyclic group wherein said cyclic group may be carbocyclic or heterocyclic with 1 to 3 heteroatoms selected from O, S, and -N(R¹¹)- with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; said cyclic group is saturated or partially unsaturated; aromatic or non-aromatic; 1 or 2 of the carbon atoms in said cyclic group optionally may be replaced by an oxo -C(O)- moiety; and said cyclic group is optionally substituted by 1 to 3 R¹⁰ groups; and R⁸ is -(CH₂)_t(C₆-C₁₀ aryl) or -(CH₂)_t(4-10 membered heterocyclic), wherein t is an integer ranging from 0 to 5 and said R⁸ group is optionally substituted by 1 to 3 R¹⁰ groups. More specific embodiments of the invention include the described method wherein R⁸ is phenyl or pyrimidyl, and R³ and R⁴ are taken together to form a group selected from

50

55

5

10



and said R⁸, R³ and R⁴ groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, methoxy, trifluoromethyl, methanesulfonyl, amino, trifluoromethoxy, acetamido, and C₁-C₆ alkyl.

[0026] Specific embodiments of the invention include a method of treating or preventing a novelty-seeking, comprising administering to the subject an effective amount of any of the following compounds of formula IV:

- (2' α ,3' $\alpha\beta$,5' α ,6' $\alpha\beta$)-5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-hexahydro-pentalene-2'-one;
- (2' α ,3' $\alpha\beta$,5' α ,6' $\alpha\beta$)-5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-2'-phenyl-octahydro-pentalen-2'ol, maleate salt;
- (2' α ,3' $\alpha\beta$,5' α ,6' $\alpha\beta$)-5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-hexahydro-pentalene-2-one, ethylene ketal;
- (2' α ,3' $\alpha\beta$,5' α ,6' $\alpha\beta$)-5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-hexahydro-pentalene-2-one;
- (2' α ,3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-[4-(5'-hydroxy-5'-phenyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, maleate salt;
- (2 α ,3 $\alpha\beta$,5 α ,6 $\alpha\beta$)-5-Hydroxy-5-phenyl-hexahydro-pentalen-2-one;
- (2' α ,3' $\alpha\beta$,5' α ,6' $\alpha\beta$)-5'-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-2'-phenyl-octahydro-pentalen-2'ol, maleate salt;
- (2' α ,3' $\alpha\beta$,5' α ,6' $\alpha\beta$)-5'-[4-(4-Fluoro-1-pyrimidyl)-piperazin-1-yl]-2'-(4-fluoro-phenyl)-octahydro-pentalen-2'ol, maleate salt;
- (2' α ,3' $\alpha\beta$,5' α ,6' $\alpha\beta$)-5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-2'-(4-fluoro-phenyl)-octahydro-pentalen-2'ol, maleate salt;
- (2' α ,3' $\alpha\beta$,5' α ,6' $\alpha\beta$)-5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-2'-(4-fluoro-phenyl)-octahydro-pentalen-2'ol, maleate salt;
- (2' α ,3' $\alpha\beta$,6' $\alpha\beta$)-1-(4-Fluoro-phenyl)-4-(5'-phenyl-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl)-piperazine dihydrochloride;
- (2' α , 3' $\alpha\beta$, 6' $\alpha\beta$)-5-Fluoro-2-[4-(5'-phenyl-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl)-piperazin-1-yl]-pyrimidine maleate;
- (2' α ,3' $\alpha\beta$,6' $\alpha\beta$)-2-Fluoro-4-[4-(5'-phenyl-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, maleate;
- (2' α ,3' $\alpha\beta$,6' $\alpha\beta$)-2-Fluoro-4-{4-[5-(2-methoxy-phenyl)-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;
- (2' α ,3' $\alpha\beta$, 6' $\alpha\beta$)-1-Phenyl-4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazine, dimaleate;
- (2' α ,3' $\alpha\beta$,5' α ,6' $\alpha\beta$)-1-(4-Fluoro-phenyl)-4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazine, dihydrochloride;
- (2' α ,3' $\alpha\beta$,5' α ,6' $\alpha\beta$)-5-Fluoro-2-[4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-pyrimidine, maleate;
- (2' α ,3' $\alpha\beta$,5' α ,6' $\alpha\beta$)-2-Fluoro-4-[4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, maleate;
- (2' α ,3' $\alpha\beta$,6' $\alpha\beta$)-1-Phenyl-4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazine, maleate;
- (2' α ,3' $\alpha\beta$,5' α ,6' $\alpha\beta$)-5'-Hydroxy-5'-(2-trifluoromethyl-phenyl)-hexahydro-pentalen-2'-one;
- (2' α ,3' $\alpha\beta$,6' $\alpha\beta$)-5'-(2-trifluoromethyl-phenyl)-3,3a,4,6a-tetrahydro-1H-pentalen-2'-one, ethylene ketal;
- (2' α ,3' $\alpha\beta$,5' α ,6' $\alpha\beta$)-5'-(2-Trifluoromethyl-phenyl)-hexahydro-1H-pentalen-2'-one, ethylene ketal;
- (2' α ,3' $\alpha\beta$,5' α ,6' $\alpha\beta$)-5'-(2-Trifluoromethyl-phenyl)-hexahydro-1H-pentalen-2'-one;
- (2' α ,3' $\alpha\beta$,5' α ,6' $\alpha\beta$)-2-Fluoro-4-{4-[5'-(2-trifluoromethyl-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;
- (2' α ,3' $\alpha\beta$,5' α ,6' $\alpha\beta$)-2-Fluoro-4-{4-[5'-(2-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;
- (2' α ,3' $\alpha\beta$,5' α ,6' $\alpha\beta$)-5-Fluoro-2-{4-[5'-(2-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-pyrimidine, maleate;
- (2' α ,3' $\alpha\beta$,5' α ,6' $\alpha\beta$)-2-Fluoro-4-{4-[5'-(3-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;
- (2' α ,3' $\alpha\beta$,5' α ,6' $\alpha\beta$)-2-Fluoro-4-{4-[5'-(4-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;

(2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-2-Fluoro-4-[4-(5'-o-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, maleate;
 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-5-Fluoro-2-[4-(5'-o-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-pyrimidine, maleate;
 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-5-Chloro-2-{4-[5'-(2-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-pyrimidine, maleate;

5 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-5-Chloro-2-[4-(5'-o-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-pyrimidine, maleate;
 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-2-Fluoro-4-[4-[5'-(2-methanesulfonyl-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile, maleate;

10 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-1-Phenyl-4-[5'-(3-pyrrolidin-1-ylmethyl-phenyl)-octahydro-pentalen-2'-yl]-piperazine, di-maleate;
 5-Trimethylstannayl-3,3a,4,6a-tetrahydro-1H-pentalen-2-one, ethylene ketal;
 5-(2-Cyano-phenyl)-3,3a,4,6a-tetrahydro-1H-pentalen-2-one;

15 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-2-Cyano-4-{4-[5'-(2-fluoro-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;
 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-2-Fluoro-4-{4-[5'-(2-trifluoromethoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;

20 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-2-Fluoro-4-{4-[5'-(2-fluoro-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;
 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-2-Fluoro-4-[4-(5'-pyridin-2-yl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, dihydro-chloride;

25 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-2-Fluoro-4-[4-(5'-m-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, maleate;
 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-2-Fluoro-4-[4-(5'-p-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, maleate;
 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-N-(2-{5'-(4-(5-Fluoro-pyrimidin-2-yl)-piperazin-1-yl)-octahydro-pentalen-2'-yl}-phenyl)-acetamide, maleate;

30 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-N-(2-{5'-(4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl)-octahydro-pentalen-2'-yl}-phenyl)-acetamide, maleate;
 5-(2-Cyano-phenyl)-3,3a,4,6a-tetrahydro-1H-pentalen-2-one, ethylene ketal;
 2-(5-Oxo-octahydro-pentalen-2-yl)-benzamide, ethylene ketal;

35 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-2-{5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl}-benzamide, maleate;
 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-2-Fluoro-4-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydrospiro[isobenzofuran-1(3H),2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-benzonitrile, maleate;

40 (2['] α , 3['] $\alpha\beta$, 5['] β , 6['] $\alpha\beta$)-2-Fluoro-4-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydrospiro[isobenzofuran-1(3H),2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-benzo-nitrile, maleate;
 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-5-Fluoro-2-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydrospiro[isobenzofuran-1(3H),2'(1'H)-pentalen]-5'-yl)-piperazin-1-yl]-pyrimidine;

45 (2['] β , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-5-Fluoro-2-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydrospiro[isobenzofuran-1(3H),2'(1'H)-pentalen]-5'-yl)-piperazin-1-yl]-pyrimididine;
 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-5-Fluoro-2-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydro-3'a,6'a-dimethylspiro[isobenzofuran-1(3H), 2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-pyrimidine, maleate;

50 (2['] β , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-5-Fluoro-2-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydro-3'a,6'a-dimethylspiro[isobenzofuran-1(3H), 2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-pyrimidine, maleate;

55 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-2-Fluoro-4-[4-(3', 3'a, 4, 4', 5', 6', 6'a-hexa-hydrospiro[2H-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-benzonitrile, maleate;
 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-1-Phenyl-4-(3', 3'a, 4, 4', 5', 6', 6'a-hexahydrospiro[2H-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl)-5'-yl)-piperazine, maleate;
 (2['] β , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-1-Phenyl-4-(3, 3', 3'a, 4, 4', 5', 6', 6'a-hexahydrospiro[2H-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl]-5'-yl)-piperazine, maleate;

55 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-2-Fluoro-4-[4-(3, 3', 3'a, 4, 4', 5', 6', 6'a-hexahydrospiro[2H-6-fluoro-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl]-5'-yl)-1-piperazinyl]-benzonitrile, maleate;

(2['] β , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-2-Fluoro-4-[4-(3, 3', 3'a, 4, 4', 5', 6', 6'a-hexahydrospiro[2H-6-fluoro-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl]-5'-yl)-1-piperazinyl]-benzonitrile, maleate;

(2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-5-Benzylamino-hexahydro-pentalen-2-one, mono -ethylene ketal;
 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-5-Amino-hexahydro-pentalen-2-one, mono-ethylene ketal;

(2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-5-(5-Fluoro-2-nitro-phenylamino)-hexahydro-pentalen-2-one, mono - ethylene ketal;
 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-5-(2-Amino-5-fluoro-phenylamino)-hexahydro-pentalen-2-one, mono - ethylene ketal;
 (2['] α , 3['] $\alpha\beta$, 5['] α , 6['] $\alpha\beta$)-2-Fluoro-4-(4-[5'-(6-fluoro-2-oxo-2,3-dihydro-benzimidazol-1-yl)-octahydro-pentalen-2'-yl]-

5 piperazin-1-yl)-benzonitrile, dimesylate;
 (2 α , 3'a β , 5' α , 6'a β)-2-Fluoro-4-{5'-(2-oxo-2,3-dihydro-benzimidazol-1-yl)-octahydro-pentalen-2'-yl}-piperazin-1-yl)-benzonitrile, mesylate;
 (2 α , 3'a β , 5' α , 6'a β)-1-{5'-[4-(5-Fluoro-pyrimidin-2-yl)-piperazin-1-yl]-octahydro-pentalen-2'-yl}-1,3-dihydro-benzimidazol-2-one, mesylate;
 (2 α , 3'a β , 5' α , 6'a β)-5-(6-Fluoro-2-methyl-benzimidazol-1-yl)-hexahydro-pentalen-2-one;
 (2 α , 3'a β , 5' α , 6'a β)-2-Fluoro-4-{4-[5'-(6-fluoro-2-methylbenzimidazol-1-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, dimesylate;
 (2 α , 3'a β , 5' α , 6'a β)-6-Fluoro-2-methyl-1-[5'-(4-phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-1H-benzimidazole, dimaleate;
 (2 α , 3'a β , 6'a β)-5-(1H-Indol-3-yl)-3,3a,4,6a-tetrahydro-1H-pentalen-2-one, mono-ethylene ketal;
 (2 α , 3'a β , 5' α , 6'a β)-2-Fluoro-4-{4-[5'-(1H-indol-3-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;
 (2 α , 3'a β , 5' α , 6'a β)-3-[5'-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-1H-indole, maleate;
 (2 α , 3'a β , 6'a β)-5-(4-Fluoro-phenoxy)-hexahydro-pentalen-2-one;
 (2 α , 3'a β , 5' β , 6'a β)-1-[5'-(4-Fluoro-phenoxy)-octahydro-pentalen-2'-yl]-4-phenyl-piperazine, maleate;
 (2 α , 3'a β , 5' β , 6'a β)-2-Fluoro-4-{4-[5'-(4-fluoro-phenoxy)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;
 (2 α , 3'a β , 5' β , 6'a β)-5-Fluoro-2-{4-[5'-(4-fluoro-phenoxy)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-pyrimidine, maleate;
 (2' β , 3'a β , 5' β , 6'a β)-1-[5'-(4-Fluoro-phenoxy)-octahydro-pentalen-2'-yl]-4-phenyl-piperazine, maleate;
 (2 α , 3'a β , 5' β , 6'a β)-2-[5'-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-isoindole-1,3-dione maleate;
 (2 α , 3'a β , 5' α , 6'a β)-5-Hydroxy-hexahydro-pentalen-2-one, ethylene ketal;
 (2 α , 3'a β , 5' α , 6'a β)-2-Oxo-3-(5-oxo-octahydro-pentalen-2-yl)-2,3-dihydro-benzimidazole-1-carboxylic acid tert-butyl ester, ethylene ketal;
 (2 α , 3'a β , 5' α , 6'a β)-2-(5-oxo-octahydro-pentalen-2-yloxy)-3H-benzimidazole-1-carboxylic acid tert-butyl ester, ethylene ketal;
 (2' β , 3'a β , 5' α , 6'a β)-3-{5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl}-2-oxo-2,3-dihydro-benzimidazole-1-carboxylic acid tert-butyl ester;
 (2' β , 3'a β , 5' α , 6'a β)-1-{5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl}-1,3-dihydro-benzimidazol-2-one, maleate;
 (2 α , 3'a β , 5' β , 6'a β)-2-Fluoro-4-{4-[5'-(2-oxo-2,3-dihydro-benzimidazol-1-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;
 (2' β , 3'a β , 5' α , 6'a β)-1-{5'-[4-(3,4-Difluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl}-1,3-dihydro-benzimidazol-2-one, maleate;
 (2' β , 3'a β , 5' α , 6'a β)-2-[5'-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yloxy]-1H-benzimidazole, maleate;
 (2 α , 3'a β , 5' α , 6'a β)-2-(5-Oxo-octahydro-pentalen-2-yl)-isoindole-1,3-dione;
 (2 α , 3'a β , 5' β , 6'a β)-2-[5'-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-isoindole-1,3-dione, maleate;
 (2 α , 3'a β , 5' β , 6'a β)-4-{4-[5'-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-2-fluoro-benzonitrile, maleate;
 (2 α , 3'a β , 5' β , 6'a β)-2-{5'-[4-(5-Fluoro-pyrimidin-2-yl)-piperazin-1-yl]-octahydro-pentalen-2'-yl}-isoindole-1,3-dione, maleate;
 (2' β , 3'a β , 5' α , 6'a β)-2-{5'-[4-(3,4-Difluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl}-isoindole-1,3-dione, maleate;
 (2' β , 3'a β , 5' α , 6'a β)-2-{5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl}-isoindole-1,3-dione, maleate; and,
 (2' β , 3'a β , 5' α , 6'a β)-N-[5-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2-yl]-benzamide, maleate.

Embodiments of Formula V

- 50 [0027] Preferred embodiments of the invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of the compound of formula V wherein X is nitrogen; or wherein Y and Z are each CR¹² wherein R¹² is hydrogen or fluoro; or wherein R² is hydrogen, fluoro or chloro; or wherein R³, R⁴ and R⁵ are hydrogen; or wherein R⁷ is fluoro or chloro; or wherein R⁹ is fluoro, chloro, bromo or alkoxy; or, more specifically, wherein X is nitrogen; Y and Z are each CR¹³ wherein R¹³ is hydrogen or fluoro; R² is hydrogen, fluoro or chloro; R³, R⁴ and R⁵ are hydrogen; R⁷ is fluoro or chloro; and R⁹ is fluoro, chloro, bromo or alkoxy.
 [0028] Specific preferred embodiments of the invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of any of the following compounds of formula V:

2-[4-(3-Trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-1H-indole;
 5-Fluoro-2-[4-(3-trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-1H-indole;
 5-Fluoro-2-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-1H-indole;
 5-Fluoro-2-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-1H-indole;
 5-Fluoro-2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole;
 2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-ylmethyl]-5-fluoro-1H-indole;
 5-Fluoro-2-(4-[5'-fluoro]pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole;
 2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-azaindole;
 5-Fluoro-2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-azaindole; and
 2-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-1H-azaindole.

Embodiments of Formula VI

[0029] Preferred embodiments of the invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of any of the compounds of formula VI wherein a is oxygen, b is CH₂, each of R¹, R⁴ and R⁵ is hydrogen, and each of R², R³ and R⁶ is selected, independently from hydrogen, cyano, chloro and fluoro.

[0030] Other more specific embodiments of this invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of any of the following compounds:

- (a) compounds of formula VI wherein a is oxygen;
- (b) compounds of formula VI wherein a is oxygen and b is CH₂;
- (c) compounds of formula VI wherein a is oxygen, b is CH₂ and each of R¹, R⁴ and R⁵ is hydrogen;
- (d) compounds of formula VI wherein a is oxygen, b is CH₂, each of R¹, R⁴ and R⁵ is hydrogen and R³ is fluoro, cyano or chloro;
- (e) compounds of formula VI wherein a is oxygen, b is CH₂, each of R¹, R⁴ and R⁵ is hydrogen and each of R², R³ and R⁶ is selected, independently, from hydrogen, fluoro, cyano and chloro; and
- (f) compounds of formula VI wherein a is oxygen, b is CH₂, each of R¹, R⁴ and R⁵ is hydrogen, and R² and R³ are selected, independently, from fluoro, cyano and chloro.

[0031] The compounds of formula I, II, III, IV, V and VI above may contain chiral centers and therefore may exist in different enantiomeric forms. This invention relates to a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of any of the optical isomers and all other stereoisomers of compounds of the formula I, II, III, IV, V and VI and mixtures thereof.

[0032] The compounds of formula I, II, III, IV, V and VI that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts.

[0033] Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I, II, III, IV, V and VI from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the basic compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained. The desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid.

[0034] The novel compounds of the formula I, II, III, IV, V and VI and the pharmaceutically acceptable salts thereof (herein referred to as "the therapeutic compounds of this invention") are useful as dopamine D4 receptor ligands, i.e., they possess the ability to inhibit the binding of dopamine D4 ligands to the dopamine D4 receptor in various subjects, including humans. They and other dopamine D4 receptor ligands are therefore able to function as therapeutic agents in the treatment or prevention of a variety of conditions in subjects, including humans, the treatment or prevention of which can be effected or facilitated by a decrease in binding of dopamine D4 receptor ligands with the dopamine D4 receptor, including a novelty-seeking disorder selected from pathological gambling, attention deficit disorder with hy-

peractivity disorder (ADHD), substance addiction (e.g., drug addiction and alcohol addiction) and sex addiction.

[0035] The term "dopaminergic effective amount", as used herein, refers to an amount sufficient to inhibit the binding of dopamine to a dopamine receptor.

[0036] The term "altering dopamine mediated neurotransmission", as used herein, includes but is not limited to increasing or decreasing D4 dopamine receptor mediated neurotransmission.

[0037] The term "novelty seeking disorder", as used herein, refers to a maladaptive variant of the personality trait of seeking novelty in the dimensional model of personality disorders. See DSM-IV. Examples of novelty-seeking disorders include: pathological gambling, attention deficit disorder with hyperactivity disorder (ADHD), substance addiction (e.g., drug addiction and alcohol addiction) and sex addiction.

10

Detailed Description of the Invention

[0038] The compounds of the formula I, II, III, IV, V and VI may be prepared as described below. Unless otherwise indicated in the discussion that follows, structural formulae I, II, III, IV and V are defined as above.

15

[0039] Compounds of the formula I may be prepared as described in United States Patent No. 5,852,031, issued December 22, 1998. This patent is incorporated herein by reference in its entirety.

[0040] Compounds of the formula II may be prepared as described in United States Patent No. 5,883,094, issued March 16, 1999. This patent is incorporated herein by reference in its entirety.

20

[0041] Compounds of the formula III may be prepared as described in United States Patent No. 5,889,010, issued March 30, 1999. This patent is incorporated herein by reference in its entirety.

[0042] Compounds of the formula IV may be prepared as described in United States Patent Application No. 09/300,262, filed April 27, 1999. This application is incorporated herein by reference in its entirety.

25

[0043] Compounds of the formula V may be prepared as described in PCT International Application No. PCT/IB98/01198 and designates the United States, and was published as Publication No. published as WO99/09025 on February 25, 1999. This application is incorporated herein by reference in its entirety.

[0044] Compounds of the formula VI may be prepared as described in PCT International Application No. PCT/IB97/00978, which was filed in the International Bureau on August 8, 1997 and designates the United States, and was published as Publication No. WO98/08835 on March 5, 1998. This application is incorporated herein by reference in its entirety.

30

[0045] The compounds of the formula I, II, III, IV, V and VI, herein referenced to collectively as the "therapeutic agents" and the pharmaceutically acceptable salts thereof, are useful as dopamine D4 receptor ligands. Other dopamine D4 receptor ligands that may be used in accordance with the methods of this invention are the compounds and pharmaceutically acceptable salts thereof described in the following references: United States Patent Application No. 5,877,317 issued on March 2, 1999; United States Patent Application No. 5,021,420, issued on June 4, 1991; United States Patent Application No. 5,633,376, issued on May 27, 1997; United States Patent Application, No. 5,432,177, issued on November 9, 1994; United States Patent Application No. 5,622,950, issued on April 22, 1997; PCT International Application No. PCT/EP93/01438, published as WO94/00458 on January 6, 1994; United States Patent Application No. 5,998,414, issued on December 7, 1999; United States Patent Application No. 5,968,478, issued on October 19, 1999; United States Patent Application No. 6,040,448, issued on March 21, 2000; United States Patent Application No. 6,051,605, issued on April 18, 2000; United States Patent Application No. 5,945,421, issued on August 31, 1999; and United States Patent Application No. 5,798,350, issued on August 25, 1998. Each of the foregoing patents and patent publications is incorporated herein by reference in its entirety.

35

[0046] The therapeutic compounds used in this invention can be administered orally, transdermally (e.g., through the use of a patch), parenterally or topically. Oral administration is preferred. In general, these compounds are most desirably administered in dosages ranging from about 0.1 mg up to about 1000 mg per day, or 1 mg to 1000 mg per day in some cases, although variations may occur depending on the weight and condition of the person being treated and the particular route of administration chosen. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.

40

[0047] The therapeutic compounds used in the invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by either of the two routes previously indicated, and such administration may be carried out in single or multiple doses. More particularly, the novel therapeutic compounds of this invention can be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, for example. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored.

[0048] For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type 5 may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

[0049] For parenteral administration, solutions of a therapeutic compound used in the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intra-articular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

[0050] Additionally, it is also possible to administer the compounds used in the present invention topically when treating inflammatory conditions of the skin and this may preferably be done by way of creams, jellies, gels, pastes, ointments and the like, in accordance with standard pharmaceutical practice.

[0051] Dopaminergic activity of the compounds used in the invention is related to the ability of the compounds to bind to the D₄ receptors, and the relative ability of compounds of this invention to inhibit [³H]-spiperone binding to human dopamine D₄ receptor subtypes expressed in clonal cell lines was measured using the following procedure.


[0052] The determination of D₄ receptor binding ability has been described by Van Tol et al., Nature, 350, 610 (1991)). Clonal cell lines expressing the human dopamine D₄ receptor are harvested and homogenized (polytron) in a 50 mM Tris:HCl (pH 7.4 at 4°C) buffer containing 5 mM EDTA, 1.5 mM calcium chloride (CaCl₂), 5 mM magnesium chloride (MgCl₂), 5mM potassium chloride (KCl) and 120 mM sodium chloride (NaCl). The homogenates are centrifuged for 10-15 min. at 48,000 g, and the resulting pellets resuspended in a buffer at a concentration of 150-250 mg/ml. For saturation experiments, 0.75 ml aliquots of tissue homogenate are incubated in triplicate with increasing concentrations 25 of [³H] spiperone (70.3 Ci/mmol; 10-3000 pM final concentration) for 30-120 minutes at 22°C in a total volume of 1 ml. For competition binding experiments, assays are initiated by the addition of 0.75 ml of membrane and incubated in duplicate with the indicated concentrations of competing ligands (10⁻¹⁴-10⁻³ M) and/or [³H]spiperone (100-300 pM) for 30 60-120 min at 22°C. Assays are terminated by rapid filtration through a Brandell cell harvester and the filters subsequently monitored for tritium as described by Sunahara, R.K. et al., Nature, 346, 76-80 (1990). For all experiments, specific [³H]spiperone binding is defined as that inhibited by 1-10 mM (+)-butaclamol. Binding data are analyzed by non-linear least squares curve-fitting. All of the compounds recited herein which were tested in this assay were found 35 to have binding affinities (K_i) for the displacement of [³H]-spiperone of less than 2 micromolar.

[0053] Utility of the present invention may be determined for the recited dopamine D₄ ligands by administering any of the ligands to subjects deemed to be suffering from a novelty-seeking disorder as determined from a Temperament and Character Inventory (Cloninger et al, Arch. Gen. Psychiatry, 50, 975-990 (1993)) and comparing the Novelty Seeking scores prior to and after the administration of the ligand. (See Malhotra et al., Mol. Psychiatry, 1, 388-391 (1996)). An improved Novelty Seeking score indicates an effective ligand dosage for administration to a subject in need of treatment.

45 Claims

1. The use of:

50 (a) a compound of the formula



10

wherein Ar is phenyl, naphthyl, benzoxazolonyl, indolyl, indolonyl, benzimidazolyl, quinolyl, furyl, benzo-furyl, thienyl, benzothienyl, oxazolyl, benzoxazolyl;

Ar¹ is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzisoxazolyl, or benzisothiazolyl;

A is O, S, SO, SO₂, C=O, CHO, or -(CR³R⁴)-;

15

n is 0, 1 or 2;

each of Ar and Ar¹ may be independently and optionally substituted with one to four substituents independently selected from the groups consisting of fluoro, chloro, bromo, iodo, cyano, nitro, thiocyanato, -SR, -SOR, -SO₂R, -NHSO₂R, -(C₁-C₆)alkoxy, -NR¹R², -NRCOR¹, -CONR¹R², Ph, -COR, COOR, -(C₁-C₆)alkyl, -(C₁-C₆)alkyl substituted with one to six halogens, -(C₃-C₆)cycloalkyl, and trifluoromethoxy;

20

each and every R, R₁, and R₂ is independently selected from the group consisting of hydrogen, -(C₁-C₆)alkyl, -(C₁-C₆)alkyl substituted with one to thirteen halogens selected from fluorine, chlorine, bromine and iodine, phenyl, benzyl, -(C₂-C₆)alkenyl, -(C₃-C₆)cycloalkyl, and -(C₁-C₆)alkoxy;


each and every R³ and R⁴ is independently selected from a group consisting of hydrogen, methyl, ethyl, n-propyl, and i-propyl;

25

or a diastereomeric or optical isomer thereof; or a pharmaceutically acceptable salt thereof; or

(b) a compound of the formula

30



40

wherein X¹, X² and X³ are independently selected from carbon and nitrogen;

R⁰, R¹ and R² are independently selected from hydrogen, halo (e.g., chloro, fluoro, bromo or iodo), (C₁-C₆)alkyl optionally substituted with from one to three fluorine atoms and (C₁-C₆)alkoxy optionally substituted with from one to three fluorine atoms;

45

R³ is hydrogen, (C₁-C₆)alkyl or benzyl, wherein the phenyl moiety of said benzyl group may optionally be substituted with from one or more substituents, independently selected from halo, cyano, (C₁-C₆)alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₆)alkoxy optionally substituted with from one to three fluorine atoms, (C₁-C₆)alkylsulfonyl, (C₁-C₆)alkylamino, amino, di-(C₁-C₆)alkylamino and (C₁-C₆)carboxamido;

50


R⁴, R⁵ and R⁶ are independently selected from hydrogen, halo (e.g., chloro, fluoro, bromo and iodo), cyano, (C₁-C₆)alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₆)alkoxy optionally substituted with from one to three fluorine atoms, (C₁-C₆)alkylsulfonyl, (C₁-C₆)acylamino, (phenyl)[(C₁-C₆)acyl]amino, amino, (C₁-C₆)alkylamino and di-(C₁-C₆)alkylamino;

55

with the proviso that when X³ is nitrogen, R² is absent;

or a pharmaceutically acceptable salt thereof; or

(c) a compound of the formula



wherein each of the dotted lines represents an optional double bond;

X is carbon or nitrogen;

20 R¹ is benzyl, aryl selected from phenyl, indanyl and naphthyl, or heteroaryl selected from pyridyl, thienyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, quinolyl and imidazolyl, wherein each of the foregoing aryl, heteroaryl and (C₁-C₄)alkyl groups, and the phenyl moiety of the benzyl group, may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from halo (e.g., chloro, fluoro, bromo or iodo), (C₁-C₆)alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₆)alkoxy optionally substituted with from one to three fluorine atoms, cyano, -C(=O)R⁸, aryl and heteroaryl, wherein said aryl is selected from phenyl, indanyl and naphthyl and said heteroaryl is selected from pyridyl, thienyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, quinolyl and imidazolyl;

25 R² and R³ are independently selected from hydrogen, hydroxy, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, cyano, -CONH₂ and -NHC(=O)R⁹, or R² and R³ together form an oxo group;

30 R⁴ is hydrogen, sulfur, oxygen, (C₁-C₆)alkyl, amino, -NHR¹⁰, -SR¹⁰, OR¹⁰ or hydroxy;

35 R⁵, R⁶ and R⁷ are independently selected from hydrogen, halo (e.g., chloro, fluoro, bromo or iodo), cyano, (C₁-C₆)alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₆)alkoxy optionally substituted with from one to three fluorine atoms, (C₁-C₆)alkylsulfonyl, (C₁-C₆)acylamino, (phenyl)[(C₁-C₆)acyl]amino, amino, (C₁-C₆)alkylamino, di-(C₁-C₆)alkylamino, aryl and heteroaryl, wherein said aryl is selected from phenyl, naphthyl and indanyl, and said heteroaryl is selected from pyridyl, thienyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, quinolyl and imidazolyl;


40 R⁸, R⁹ and R¹⁰ are independently selected from hydrogen and (C₁-C₆)alkyl; and

R¹¹ is hydrogen, (C₁-C₆)alkyl or benzyl, wherein the phenyl moiety of said benzyl may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from halo (e.g., fluoro, chloro, bromo, or iodo), (C₁-C₆)alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₆)alkoxy optionally substituted with from one to three fluorine atoms, amino, cyano, (C₁-C₆)alkylamino and di-(C₁-C₆)alkylamino;

45 with the proviso that: (a) R⁴ can not be either oxygen or hydroxy when both R² and R³ are hydrogen; (b) when the five membered ring of formula I contains a double bond, R¹¹ is absent; (c) when R⁴ is sulfur or oxygen, R⁴ is double bonded to the carbon to which is attached and such carbon is single bonded to both adjacent ring nitrogen atoms; and (d) when X is nitrogen and is double bonded to an adjacent carbon, R¹ is absent.

50 or a pharmaceutically acceptable salt thereof; or

(d) a compound of the formula



or a pharmaceutically acceptable salt or solvate thereof wherein:

the dashed line in the above formula represents an optional double bond where X^2 is not O;

15 X^1 and X^2 are each independently selected from O and $-(CH_2)_j$, wherein j is 1 or 2;

X^3 is $-CH(R^5)N(R^8)CH(R^6)$, $-CH(R^5)C(R^8)(R^9)CH(R^6)$, $-C(R^5)=C(R^8)CH(R^6)$, or $-CH(R^5)C(R^8)=C(R^6)$; R^1 and R^2 are each independently H, hydroxy, or C_1-C_6 alkyl; or R^1 and R^2 are taken together as a bond; each R^3 is independently selected from $-S(O)_jR^7$ wherein j is an integer ranging from 0 to 2, $-C(O)R^7$, $-OR^7$, $-NC(O)R^7$, $-NR^7R^{12}$, and the substituents provided in the definition of R^7 other than H;

20 R^4 is absent where the dashed line in the above formula 1 represents a double bond or R^4 is selected from H and the substituents provided in the definition of R^3 ; or R^3 and R^4 are taken together with the carbon atom to which each is attached to form a 5-10 membered mono-cyclic or bicyclic group wherein said cyclic group may be carbocyclic or heterocyclic with 1 to 3 heteroatoms selected from O, S, and $-N(R^{11})$ with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; said cyclic group is saturated or partially unsaturated; aromatic or non-aromatic; 1 or 2 of the carbon atoms in said cyclic group optionally may be replaced by an oxo $-C(O)-$ moiety; and said cyclic group is optionally substituted by 1 to 3 R^{10} groups;

25 R^5 and R^6 are each independently selected from H and C_1-C_4 alkyl; or R^5 and R^6 are taken together as $-(CH_2)_q$, wherein q is 2 or 3; or R^5 or R^6 is taken together with R^8 as defined below; each R^7 is independently selected from H, $-(CH_2)_t(C_6-C_{10}$ aryl) and $-(CH_2)_t(4-10$ membered heterocyclic), wherein t is an integer ranging from 0 to 5; 1 or 2 of the carbon atoms of said heterocyclic group optionally may be replaced with an oxo $-C(O)-$ group; said aryl and heterocyclic R^7 groups are optionally fused to a benzene ring, a C_5-C_8 saturated cyclic group, or a 4-10 membered heterocyclic group; the $-(CH_2)_t$ moieties of the foregoing R^7 groups optionally include a carbon-carbon double or triple bond where t is an integer between 2 and 5; and the foregoing R^7 groups, except H, are optionally substituted by 1 to 5 R^{10} groups;


30 R^8 is selected from the substituents provided in the definition of R^7 other than H;

35 R^9 is selected from the substituents provided in the definition of R^7 ; or R^8 and R^9 are taken together with the carbon to which each is attached to form a 5-10 membered mono-cyclic or bicyclic group wherein said cyclic group is carbocyclic or heterocyclic with 1 to 3 heteroatoms selected from O, S, and $-N(R^{11})$ with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; saturated or partially unsaturated; aromatic or non-aromatic; 1 or 2 of the carbon atoms in said cyclic group optionally may be replaced by an oxo $-C(O)-$ moiety; and said cyclic group is optionally substituted by 1 to 3 R^{10} groups; or R^8 taken together with either R^5 or R^6 and the separate carbon atoms to which each is attached to form a fused 5-10 membered mono-cyclic or bicyclic group wherein said cyclic group may be carbocyclic or heterocyclic with 1 to 3 heteroatoms selected from O, S, and $-N(R^{11})$ with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; saturated or partially unsaturated; aromatic or non-aromatic; 1 or 2 of the carbon atoms in said cyclic group optionally may be replaced by an oxo $-C(O)-$ moiety; and said cyclic group is optionally substituted by 1 to 3 R^{10} groups;

40 R^{10} is independently selected from C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-OR^{11}$, $-C(O)R^{11}$, $-C(O)OR^{11}$, $-NR^{12}C(O)OR^{11}$, $-OC(O)R^{11}$, $-NR^{12}SO_2R^{11}$, $-SO_2NR^{11}R^{12}$, $-NR^{12}C(O)R^{11}$, $-C(O)NR^{11}R^{12}$, $-NR^{11}R^{12}$, $-S(O)_j(C_1-C_6$ alkyl) wherein j is an integer ranging from 0 to 2, $-(CH_2)_m(C_6-C_{10}$ aryl), $-SO_2(CH_2)_m(C_6-C_{10}$ aryl), $-S(CH_2)_m(C_6-C_{10}$ aryl), $-O(CH_2)_m(C_6-C_{10}$ aryl) and $-(CH_2)_m(4-10$ membered heterocyclic), wherein m is an integer ranging from 0 to 4; said C_1-C_{10} alkyl group optionally contains 1 or 2 hetero moieties selected from O, S and $-N(R^{12})$ with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; said aryl and heterocyclic R^{10} groups are optionally fused to a C_6-C_{10} aryl group, a C_5-C_8 saturated

cyclic group, or a 4-10 membered heterocyclic group; and said alkyl, aryl and heterocyclic R¹⁰ groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -NR¹²SO₂R¹¹, -SO₂NR¹¹R¹², -C(O)R¹¹, -C(O)OR¹¹, -OC(O)R¹¹, -NR¹²C(O)R¹¹, -C(O)NR¹¹R¹², -NR¹¹R¹², C₁-C₆ alkyl, -OR¹¹ and the substituents listed in the definition of R¹¹; each R¹¹ is independently selected from H, C₁-C₁₀ alkyl, -(CH₂)_m(C₆-C₁₀ aryl), and -(CH₂)_m(4-10 membered heterocyclic), wherein m is an integer ranging from 0 to 4; said alkyl group optionally includes 1 or 2 hetero moieties selected from O, S and -N(R¹²)-, with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; said aryl and heterocyclic R¹¹ groups are optionally fused to a C₆-C₁₀ aryl group, a C₅-C₈ saturated cyclic group, or a 4-10 membered heterocyclic group; and the foregoing R¹¹ substituents, except H, are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -C(O)R¹², -C(O)OR¹², -CO(O)R¹², -NR¹²C(O)R¹³, -C(O)NR¹²R¹³, -NR¹²R¹³, hydroxy, C₁-C₆ alkyl, and C₁-C₆ alkoxy; and, each R¹² and R¹³ is independently H or C₁-C₆ alkyl; or


(e) a compound of the formula



or a pharmaceutically acceptable salt thereof, wherein the broken line represents an optional double bond;

a is 0 or 1, wherein when a is 0, X may form an optional double bond with the carbon adjacent to V;
 V is CHR¹⁰ wherein R¹⁰ is hydrogen or (C₁-C₆)alkyl;
 T is nitrogen or CH;
 X is nitrogen or CR¹¹ wherein R¹¹ is hydrogen, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, hydroxy or cyano;
 Y and Z are each independently nitrogen or CR¹² wherein R¹² is hydrogen, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano, (C₁-C₆)alkoxy or (C₁-C₆)alkyl;
 R¹ is hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano or (C₁-C₆)alkyl;
 R², R⁶, R⁷, R⁸ and R⁹ are each independently selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano, (C₁-C₆)alkoxy and (C₁-C₆)alkyl;
 R³ and R⁴ are each independently hydrogen or (C₁-C₆)alkyl; and
 R⁵ is hydrogen, (C₁-C₆)alkoxy, trifluoromethyl, cyano, (C₁-C₆)alkyl or R¹³CO- wherein R¹³ is amino, (C₁-C₆)alkylamino, ((C₁-C₆)alkyl)₂amino, (C₁-C₆)alkyl, (C₆-C₁₀)aryl;

or when a is 1, R¹ and R¹⁰ may be taken together with the carbons to which they are attached to form a compound of the formula



wherein the broken lines represent optional bonds;

T, X, Y, Z, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ are defined as above;

b is 0 or 1; and


A and B are each independently CH, CH₂, oxygen, sulfur, NH or nitrogen;

with the proviso that when X is nitrogen, the optional double bond between X and V does not exist;

with the proviso that when b is 0, the optional double bond between A and B does not exist; and

with the proviso that when b is 1, A and B cannot both be oxygen or sulfur; or

10 (f) a compound of the formula



wherein a is oxygen, CH₂, C(CH₃)₂, NR¹⁰, sulfur, SO or SO₂;

b is oxygen, CH₂, C=O, C=NR¹¹, C=NOH, SO₂; Sulfur, SO, C=NO(C₁-C₅)alkyl or CR⁷R⁸;

25 each of R¹ through R⁸ is selected, independently, from hydrogen, halo (e.g., chloro, fluoro, bromo or iodo), trifluoromethyl, cyano and hydroxy, or R⁷ and R⁸ together can be C(=O)NH₂ or C(=O)N(C₁-C₄)alkyl, with the proviso that neither R⁷ nor R⁸ can be halo when a is oxygen, NR¹¹, sulfur, SO or SO₂; and each of R¹⁰ and R¹¹ is selected, independently, from hydrogen, benzyl and (C₁-C₆)alkyl;

30 or a pharmaceutically acceptable salt thereof;

in the manufacture of a medicament for the treatment or prevention of a novelty-seeking disorder.

2. The use of claim 1, wherein the novelty-seeking disorder is selected from pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction, drug addiction, alcohol addiction and sex addiction.

35 3. The use of claim 1, wherein the compound is selected from:

(7R,9aS)-7-(4-fluorophenoxy)methyl-2-(5-fluoropyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

40 (7R,9aS)-7-(3,4-difluorophenoxy)-methyl-2-(5-fluoropyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7R,9aS)-7-(4-fluorophenoxy)methyl-2-(5-chloropyridin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

45 2-(5-fluoropyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2a]-pyrazin-7-ylmethyl]-3H-benzoxazol-2-one hydrochloride;

3-[(7R,9aS)-2-(5-chloropyridin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazin-7-ylmethyl]-3H-benzoxazol-2-one; and

((7S,9aS)-7-(3-cyanophenoxy)methyl-2-(5-fluoropyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine.

50 4. The use of claim 1, wherein the compound is selected from:

1-[3-(4-pyridin-2-yl-piperazin-1-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one;

1-[3-(4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one;

55 1-[3-(4-(5-chloro-pyridin-2-yl)-piperazin-1-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one;

1-[3-(4-(5-bromo-pyridin-2-yl)-piperazin-1-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one;

1-[3-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one; and

1-[3-(4-(6-chloro-pyridazin-3-yl)-piperazin-1-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one.

5. The use of claim 1, wherein the compound is selected from:

1-Benzimidazol-1-yl-3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propan-2-ol;
 1-(5-Chloro-benzimidazol-1-yl)-3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propan-2-ol;
 5 1-{3-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-propyl}-5-trifluoromethyl-1H-benzimidazole;
 1-{3-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-propyl}-1H-benzimidazole;
 1-{3-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-propyl}-3-methyl-1,3-dihydro-benzimidazol-2-one;
 10 1-Benzimidazol-1-yl-3-(4-o-tolyl-piperazine-1-yl)-propan-2-ol;
 1-Benzimidazol-1-yl-3-(4-m-tolyl-piperazine-1-yl)-propan-2-ol;
 1-Benzimidazol-1-yl-3-(4-p-tolyl-piperazin-1-yl)-propan-2-ol;
 1-Benzimidazol-1-yl-3-{4-chloro-phenyl}-phenyl-methyl]-piperazin-1-yl]-propan-2-ol;
 1-Benzimidazol-1-yl-3-[4-(2-chloro-phenyl)-piperazin-1-yl]-propan-2-ol;
 1-Benzimidazol-1-yl-3-[4-(4-chloro-phenyl)-piperazin-1-yl]-propan-2-ol;
 15 1-Benzimidazol-1-yl-3-[4-(3-chloro-phenyl)-piperazin-1-yl]-propan-2-ol;
 1-Benzimidazol-1-yl-3-[4-(3-chloro-phenyl)-piperazin-1-yl]-propan-2-ol;
 1-Benzimidazol-1-yl-3-(4-pyrimidin-2-yl-piperazin-1-yl)-propan-2-ol;
 20 1-Benzimidazol-1-yl-3-(4-naphthalen-1-yl-piperazin-1-yl)-propan-2-ol;
 1-Benzimidazol-1-yl-3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-propan-2-ol;
 1-Benzimidazol-1-yl-3-(4-benzyl-piperazin-1-yl)-propan-2-ol;
 1-Benzimidazol-1-yl-3-[4-(2-trifluoromethyl-benzyl)-piperazin-1-yl]-propan-2-ol;
 1-Benzimidazol-1-yl-3-[4-(2-ethoxy-benzyl)-piperazin-1-yl]-propan-2-ol;
 25 1-Benzimidazol-1-yl-3-(4-{3-(3-trifluoromethyl-phenyl)-propyl}-piperazin-1-yl)-propan-2-ol; and
 1-Benzimidazol-1-yl-3-{4-[2-(3-trifluoromethyl-phenyl)-ethyl]-piperazin-1-yl}-propan-2-ol.

25 6. The use of claim 1, wherein the compound is selected from:

(2' α ,3' α β ,5' α ,6' α β)-5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-hexahydro-pentalene-2'-one;
 (2' α ,3' α β ,5' α ,6' α β)-5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-2'-phenyl-octahydro-pentalen-2'ol, maleate salt;
 30 (2' α ,3' α β ,5' α ,6' α β)-5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-hexahydro-pentalene-2-one, ethylene ketal;
 (2' α ,3' α β ,5' α ,6' α β)-5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-hexahydro-pentalene-2-one;
 (2' α ,3' α β ,5' α ,6' α β)-2-Fluoro-4-[4-(5'-hydroxy-5'-phenyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, maleate salt;
 35 (2 α ,3a β ,5 α ,6a β)-5-Hydroxy-5-phenyl-hexahydro-pentalen-2-one;
 (2' α ,3' α β ,5' α ,6' α β)-5'-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-2'-phenyl-octahydro-pentalen-2'ol, maleate salt;
 (2' α ,3' α β ,5' α ,6' α β)-5'-[4-(4-Fluoro-1-pyrimidyl)-piperazin-1-yl]-2'-(4-fluoro-phenyl)-octahydro-pentalen-2'ol, maleate salt;
 40 (2' α ,3' α β ,5' α ,6' α β)-5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-2'-(4-fluoro-phenyl)-octahydro-pentalen-2'ol, maleate salt;
 (2' α ,3' α β ,5' α ,6' α β)-5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-2'-(4-fluoro-phenyl)-octahydro-pentalen-2'ol, maleate salt;
 (2' α ,3' α β ,6' α β)-1-(4-Fluoro-phenyl)-4-(5'-phenyl-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl)-piperazine dihydrochloride;
 45 (2' α ,3' α β ,6' α β)-5-Fluoro-2-[4-(5'-phenyl-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl)-piperazin-1-yl]-pyrimidine maleate;
 (2' α ,3' α β ,6' α β)-2-Fluoro-4-[4-(5'-phenyl-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, maleate;
 (2' α ,3' α β ,6' α β)-2-Fluoro-4-{4-[5-(2-methoxy-phenyl)-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;
 50 (2' α ,3' α β ,6' α β)-1-Phenyl-4-(5'-phenyl-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl)-piperazine, dimaleate;
 (2' α ,3' α β ,5' α ,6' α β)-1-(4-Fluoro-phenyl)-4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazine, dihydrochloride;
 (2' α ,3' α β ,5' α ,6' α β)-5-Fluoro-2-[4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-pyrimidine, maleate;
 (2' α ,3' α β ,5' α ,6' α β)-2-Fluoro-4-[4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, maleate;
 (2' α ,3' α β ,5' α ,6' α β)-1-Phenyl-4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazine, maleate;
 55 (2' α ,3' α β ,5' α ,6' α β)-5'-Hydroxy-5'-(2-trifluoromethyl-phenyl)-hexahydro-pentalen-2'-one;
 (2' α ,3' α β ,6' α β)-5'-(2-trifluoromethyl-phenyl)-3,3a,4,6a-tetrahydro-1H-pentalen-2'-one, ethylene ketal;
 (2' α ,3' α β ,5' α ,6' α β)-5'-(2-Trifluoromethyl-phenyl)-hexahydro-1H-pentalen-2'-one, ethylene ketal;
 (2' α ,3' α β ,5' α ,6' α β)-5'-(2-Trifluoromethyl-phenyl)-hexahydro-1H-pentalen-2'-one;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-{4-[5'-(2-trifluoromethyl-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-{4-[5'-(2-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;

5 (2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-5-Fluoro-2-{4-[5'-(2-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-pyrimidine, maleate;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-{4-[5'-(3-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;

10 (2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-{4-[5'-(4-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-{4-(5'-o-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl}-benzonitrile, maleate;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-5-Fluoro-2-[4-(5'-o-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-pyrimidine, maleate;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-5-Chloro-2-{4-[5'-(2-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-pyrimidine, maleate;

15 (2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-5-Chloro-2-[4-(5'-o-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-pyrimidine, maleate;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-{4-[5'-(2-methanesulfonyl-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-1-Phenyl-4-[5'-(3-pyrrolidin-1-ylmethyl-phenyl)-octahydro-pentalen-2'-yl]-piperazine, di-

20 maleate;

5-Trimethylstannayl-3,3a,4,6a-tetrahydro-1H-pentalen-2-one, ethylene ketal;

5-(2-Cyano-phenyl)-3,3a,4,6a-tetrahydro-1H-pentalen-2-one;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Cyano-4-{4-[5'-(2-fluoro-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;

25 (2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-{4-[5'-(2-trifluoromethoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-{4-[5'-(2-fluoro-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-[4-(5'-pyridin-2-yl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, dihy-

30 drochloride;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-[4-(5'-m-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, maleate;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-[4-(5'-p-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, maleate;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-N-(2-{5'-[4-(5-Fluoro-pyrimidin-2-yl)-piperazin-1-yl]-octahydro-pentalen-2'-yl}-phenyl)-acetamide, maleate;

35 (2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-N-(2-{5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1yl]-octahydro-pentalen-2'-yl}-phenyl)-acetamide, maleate;

5-
35-(2-Cyano-phenyl)-3,3a,4,6a-tetrahydro-1H-pentalen-2-one, ethylene ketal;

2-(5-Oxo-octahydro-pentalen-2-yl)-benzamide, ethylene ketal;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-{5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl}-benzamide, maleate;

40 (2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydrospiro[isobenzofuran-1(3H), 2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-benzonitrile, maleate;

(2' α , 3' $\alpha\beta$, 5' β , 6' $\alpha\beta$)-2-Fluoro-4-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydrospiro[isobenzofuran-1(3H), 2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-benzonitrile, maleate;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-5-Fluoro-2-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydrospiro[isobenzofuran-1(3H), 2'(1'H)-pentalen]-5'-yl)-piperazin-1-yl]-pyrimidine;

45 (2' β , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-5-Fluoro-2-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydrospiro[isobenzofuran-1(3H), 2'(1'H)-pentalen]-5'-yl)-piperazin-1-yl]-pyrimidine;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-5-Fluoro-2-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydrospiro[isobenzofuran-1(3H), 2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-pyrimidine, maleate;

50 (2' β , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-5-Fluoro-2-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydrospiro[isobenzofuran-1(3H), 2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-pyrimidine, maleate;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-[4-(3', 3'a, 4, 4', 5', 6', 6'a-hexahydrospiro[2H-1-benzopyran-2, 2'(1'H)-pen-

55 talen]-5'-yl)-1-piperazinyl]-benzonitrile, maleate;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-[4-(3', 3'a, 4, 4', 5', 6', 6'a-hexahydrospiro[2H-1-benzopyran-2, 2'(1'H)-pen-

talen]-5'-yl)-1-piperazinyl]-benzonitrile, maleate;

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-1-Phenyl-4-(3', 3'a, 4, 4', 5', 6', 6'a-hexahydrospiro[2H-1-benzopyran-2, 2'(1'H)-pen-

talen]-5'-yl)-piperazine, maleate;

(2' β , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-1-Phenyl-4-(3', 3'a, 4, 4', 5', 6', 6'a-hexahydrospiro[2H-1-benzopyran-2, 2'(1'H)-pen-

talen]-5'-yl]-5'-yl)-piperazine, maleate;
 (2 α , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-2-Fluoro-4-[4-(3, 3 α , 4, 4 β , 5 β , 6 β , 6'a-hexahydrospiro[2H-6-fluoro-1-benzopyran-2,2'
 (1'H)-pentalen]-5'-yl]-5'-yl)-1-piperazinyl]-benzonitrile, maleate;
 (2 β , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-2-Fluoro-4-[4-(3, 3 α , 4, 4 β , 5 β , 6 β , 6'a-hexahydrospiro[2H-6-fluoro-1-benzopyran-2,2'
 (1'H)-pentalen]-5'-yl]-5'-yl)-1-piperazinyl]-benzonitrile, maleate;
 (2 α , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-5-Benzylamino-hexahydro-pentalen-2-one, mono -ethylene ketal;
 (2 α , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-5-(5-Fluoro-2-nitro-phenylamino)-hexahydro-pentalen-2-one, mono - ethylene ketal;
 (2 α , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-5-(2-Amino-5-fluoro-phenylamino)-hexahydro-pentalen-2-one, mono - ethylene ketal;
 (2 α , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-2-Fluoro-4-[4-[5'-(6-fluoro-2-oxo-2,3-dihydro-benzimidazol-1-yl)-octahydro-pentalen-2'-
 yl]-piperazin-1-yl]-benzonitrile, dimesylate;
 (2 α , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-2-Fluoro-4-[4-[5'-(2-oxo-2,3-dihydro-benzimidazol-1-yl)-octahydro-pentalen-2'-yl]-pip-
 erazin-1-yl]-benzonitrile, mesylate;
 (2 α , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-1-[5'-[4-(5-Fluoro-pyrimidin-2-yl)-piperazin-1-yl]-octahydro-pentalen-2'-yl]-1,3-dihydro-
 benzoimidazol-2-one, mesylate;
 (2 α , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-5-(6-Fluoro-2-methyl-benzimidazol-1-yl)-hexahydro-pentalen-2-one;
 (2 α , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-2-Fluoro-4-[4-[5'-(6-fluoro-2-methylbenzimidazol-1-yl)-octahydro-pentalen-2'-yl]-piper-
 azin-1-yl]-benzonitrile, dimesylate;
 (2 α , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-6-Fluoro-2-methyl-1-[5'-(4-phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-1H-benzoim-
 idazole, dimaleate;
 (2 α , 3 $\alpha\beta$, 6 $\alpha\beta$)-5-(1H-Indol-3-yl)-3,3 α , 4, 6a-tetrahydro-1H-pentalen-2-one, mono-ethylene ketal;
 (2 α , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-2-Fluoro-4-[4-[5'-(1H-indol-3-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile,
 maleate;
 (2 α , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-3-[5'-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-1H-indole, maleate;
 (2 α , 3 $\alpha\beta$, 6 $\alpha\beta$)-5-(4-Fluoro-phenoxy)-hexahydro-pentalen-2-one;
 (2 α , 3 $\alpha\beta$, 5 β , 6 $\alpha\beta$)-1-[5'-(4-Fluoro-phenoxy)-octahydro-pentalen-2'-yl]-4-phenyl-piperazine maleate;
 (2 α , 3 $\alpha\beta$, 5 β , 6 $\alpha\beta$)-2-Fluoro-4-[4-[5'-(4-Fluoro-phenoxy)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzon-
 trile, maleate;
 (2 α , 3 $\alpha\beta$, 5 β , 6 $\alpha\beta$)-5-Fluoro-2-[4-[5'-(4-Fluoro-phenoxy)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-pyrimidine,
 maleate;
 (2 β , 3 $\alpha\beta$, 5 β , 6 $\alpha\beta$)-1-[5'-(4-Fluoro-phenoxy)-octahydro-pentalen-2'-yl]-4-phenyl-piperazine, maleate;
 (2 α , 3 $\alpha\beta$, 5 β , 6 $\alpha\beta$)-2-[5'-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-isoindole-1,3-dione maleate;
 (2 α , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-5-Hydroxy-hexahydro-pentalen-2-one, ethylene ketal;
 (2 α , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-2-Oxo-3-(5-oxo-octahydro-pentalen-2-yl)-2,3-dihydro-benzimidazole-1-carboxylic acid
 tert-butyl ester, ethylene ketal;
 (2 α , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-2-(5-oxo-octahydro-pentalen-2-yloxy)-3H-benzimidazole-1-carboxylic acid tert-butyl es-
 ter, ethylene ketal;
 (2 β , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-3-[5'-(4-(4-Fluoro-phenyl)-piperazin-1-yl)-octahydro-pentalen-2'-yl]-2-oxo-2,3-dihydro-
 benzimidazole-1-carboxylic acid tert-butyl ester;
 (2 β , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-1-[5'-(4-(4-Fluoro-phenyl)-piperazin-1-yl)-octahydro-pentalen-2'-yl]-1,3-dihydro-ben-
 zimidazol-2-one, maleate;
 (2 α , 3 $\alpha\beta$, 5 β , 6 $\alpha\beta$)-2-Fluoro-4-[4-[5'-(2-oxo-2,3-dihydro-benzimidazol-1-yl)-octahydro-pentalen-2'-yl]-pip-
 erazin-1-yl]-benzonitrile, maleate;
 (2 β , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-1-[5'-(4-(3,4-Difluoro-phenyl)-piperazin-1-yl)-octahydro-pentalen-2'-yl]-1,3-dihydro-ben-
 zimidazol-2-one, maleate;
 (2 β , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-2-[5'-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yloxy]-1H-benzimidazole,
 maleate;
 (2 α , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-2-(5-Oxo-octahydro-pentalen-2-yl)-isoindole-1,3-dione;
 (2 α , 3 $\alpha\beta$, 5 β , 6 $\alpha\beta$)-2-[5'-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-isoindole-1,3-dione, maleate;
 (2 α , 3 $\alpha\beta$, 5 β , 6 $\alpha\beta$)-4-[4-[5'-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-
 2-fluoro-benzonitrile, maleate;
 (2 α , 3 $\alpha\beta$, 5 β , 6 $\alpha\beta$)-2-[5'-(4-(5-Fluoro-pyrimidin-2-yl)-piperazin-1-yl)-octahydro-pentalen-2'-yl]-isoindole-
 1,3-dione, maleate;
 (2 β , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-2-[5'-(4-(3,4-Difluoro-phenyl)-piperazin-1-yl)-octahydro-pentalen-2'-yl]-isoindole-1,3-di-
 one, maleate;
 (2 β , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-2-[5'-(4-(4-Fluoro-phenyl)-piperazin-1-yl)-octahydro-pentalen-2'-yl]-isoindole-1,3-dione,
 maleate; and
 (2 β , 3 $\alpha\beta$, 5 α , 6 $\alpha\beta$)-N-[5-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2-yl]-benzamide, maleate.

7. The use of claim 1, wherein the compound is selected from:

2-[4-(3-Trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-1H-indole;
5-Fluoro-2-[4-(3-trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-1H-indole;
5
5-Fluoro-2-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-1H-indole;
5-Fluoro-2-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-1H-indole;
5-Fluoro-2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole;
2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-ylmethyl]-5-fluoro-1H-indole;
5-Fluoro-2-(4-[5'-fluoro]pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole;
10
2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-azaindole;
5-Fluoro-2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-azaindole; and
2-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-1H-azaindole.

15
8. The use of a dopamine D4 receptor ligand in the manufacture of a medicament for the treatment or prevention of a novelty-seeking disorder.

9. The use of claim 8 wherein the novelty-seeking disorder is selected from pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction, drug addiction, alcohol addiction and sex addiction.

20
10. A compound, as defined in any one of claims 1 or 3 to 7 for use in the treatment or prevention of a novelty-seeking disorder.

11. A dopamine D4 receptor ligand for use in the treatment or prevention of a novelty-seeking disorder.

25
12. A compound as claimed in claim 10 or claim 11 wherein the novelty-seeking disorder is selected from pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction, drug addiction, alcohol addiction and sex addiction.

30

35

40

45

50

THIS PAGE BLANK (USPTO)

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets

(11)



EP 1 177 792 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
23.10.2002 Bulletin 2002/43

(51) Int Cl.7: A61K 31/505, A61P 25/30,
A61P 25/32, A61P 43/00

(43) Date of publication A2:
06.02.2002 Bulletin 2002/06

(21) Application number: 01306163.5

(22) Date of filing: 18.07.2001

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 27.07.2000 US 221268 P

(71) Applicant: **Pfizer Products Inc.**
Groton, Connecticut 06340 (US)

(72) Inventors:
• **Fliri, Anton Franz Josef**
Groton, Connecticut 06340 (US)

• **Sanner, Mark Allen**
Groton, Connecticut 06340 (US)
• **Seymour, Patricia Ann**
Groton, Connecticut 06340 (US)
• **Zorn, Stevin Howard**
Groton, Connecticut 06340 (US)

(74) Representative: **Ruddock, Keith Stephen et al**
Pfizer Limited,
European Patent Department,
Ramsgate Road
Sandwich, Kent CT13 9NJ (GB)

(54) Dopamine D4 Ligands for the treatment of novelty-seeking disorders

(57) The use of a dopamine D4 receptor ligand in the manufacture of a medicament for the treatment or prevention of a novelty-seeking disorder, particularly pathological gambling, attention deficit disorder with hy-

peractivity disorder, substance addiction, drug addiction, alcohol addiction and sex addiction.

EP 1 177 792 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 01 30 6163
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
D, X	US 5 852 031 A (SANNER MARK A ET AL) 22 December 1998 (1998-12-22) * abstract * * column 1, line 27 - line 31 * * column 7, line 37-41 * * column 9, line 15 - line 17 * * claims 1-17 *	2-7, 9, 10, 12	A61K31/505 A61P25/30 A61P25/32 A61P43/00
X	WO 96 10571 A (PFIZER ;DESAI KISHOR A (US); FLIRI ANTON F J (US); SANNER MARK A () 11 April 1996 (1996-04-11) * abstract * * page 1, line 8 - line 12 * * page 2, line 12 - line 17 * * page 14, line 19 - line 21 * * claims 1-32 *	2-7, 9, 10, 12	
	-/-		
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61K
INCOMPLETE SEARCH			
The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.			
Claims searched completely :			
Claims searched Incompletely :			
Claims not searched :			
Reason for the limitation of the search: see sheet C			
Place of search	Date of completion of the search	Examiner	
MUNICH	28 August 2002	Taylor, G.M.	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

European Patent
OfficeINCOMPLETE SEARCH
SHEET C

Application Number

EP 01 30 6163

Claim(s) searched incompletely:
2-7, 9, 10, 12

Claim(s) not searched:
1, 8, 11

Reason for the limitation of the search:

Present claims 1, 8 and 11 refer to the treatment of "novelty-seeking disorders". Since this term does not appear to have accepted definition in the art, the scope of protection sought is vague and indefinite. The indications searched have therefore been restricted to those given in claims 2, 9 and 12.

Moreover, present claims 1, 8 and 11 relate to an extremely large number of possible compounds. Support within the meaning of Art. 84 EPC and/or disclosure within the meaning of Art. 83 EPC is to be found, however, for only a very small proportion of the compounds, namely those explicitly named in claims 3-7.

Moreover, the application does not contain one single example - either in vivo or in vitro - of the use of a dopamine D4 receptor ligand in the treatment of any indication claimed.

In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds as defined in claims 3-7 for the treatment of the indications given in claim 2.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 01 30 6163

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	WO 96 04250 A (PFIZER ;FARACI WILLIAM S (US); FLIRI ANTON F J (US); NEILL BRIAN T) 15 February 1996 (1996-02-15) * abstract * * page 1, line 10 - line 17 * * page 2, line 11 - page 4, line 8 * * page 10, line 9 - page 12, line 10 * * claims 1-16 * —	2-7, 9, 10, 12	
X	WO 95 34555 A (FLIRI ANTON F ;SANNER MARK A (US); ZORN STEVIN H (US); NEILL BRIAN) 21 December 1995 (1995-12-21) * abstract * * page 1, line 6 - line 17 * * page 1, line 34 - page 2, line 26 * * page 5, line 3 - line 19 * * claims 1-14 * —	2-7, 9, 10, 12	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X,D	WO 96 25414 A (UPJOHN CO ;TENBRINK RUTH E (US)) 22 August 1996 (1996-08-22) * abstract * * page 1, line 4 - line 6 * * page 4, line 10 - page 10, line 25 * * page 10, line 33 * * page 11, line 13 - line 14 * * claims 1-15 * —	2-7, 9, 10, 12	
X	SANNER M A ET AL: "Synthesis, SAR and pharmacology of CP-293,019: a potent, selective dopamine D4 receptor antagonist" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 7, 7 April 1998 (1998-04-07), pages 725-730, XP004136954 ISSN: 0960-894X * the whole document * —	10, 12 —/—	



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 01 30 6163

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	TECHNICAL FIELDS SEARCHED (Int.Cl.)
D,X	WO 98 08835 A (BUTLER TODD WILLIAM ;PFIZER (US); FLIRI ANTON FRANZ JOSEPH (US)) 5 March 1998 (1998-03-05) * abstract * * page 1, line 7 - line 14 * * page 2, line 16 - page 3, line 10 * * page 3, line 27 - page 5, line 27 * * claims 1-16 *	10,12	
P,X	EP 1 074 257 A (PFIZER PROD INC) 7 February 2001 (2001-02-07) * abstract * * page 3, line 34 - page 4, line 10 * * claims 1-10 *	2-7,9, 10,12	
P,X	WO 00 76981 A (NEUROGEN CORP ;ZHAO HE (US); THURKAUF ANDREW (US)) 21 December 2000 (2000-12-21) * abstract * * page 3, line 2 - line 10 * * claims 1-47 *	12	

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 01 30 6163

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
 The members are as contained in the European Patent Office EDP file on
 The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-08-2002

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5852031	A	22-12-1998	AT 209648 T AU 681310 B2 AU 3189395 A DE 69524241 D1 DE 69524241 T2 DK 783503 T3 EP 0783503 A1 FI 971310 A JP 9511527 T JP 3287574 B2 KR 244848 B1 NO 971416 A NZ 290936 A PL 319636 A1 SI 9520096 A SK 32597 A3 BR 9504230 A CA 2200959 A1 CN 1168672 A ,B CZ 9700947 A3 ES 2166830 T3 HR 950507 A1 HU 77354 A2 WO 9610571 A1 IL 115384 A PT 783503 T RU 2163239 C2 TR 960273 A2 TW 406081 B ZA 9508223 A	15-12-2001 21-08-1997 26-04-1996 10-01-2002 13-06-2002 11-02-2002 16-07-1997 27-03-1997 18-11-1997 04-06-2002 02-03-2000 20-05-1997 26-01-1998 18-08-1997 30-04-1998 09-09-1998 06-08-1996 11-04-1996 24-12-1997 15-07-1998 01-05-2002 31-08-1997 30-03-1998 11-04-1996 28-10-1999 28-03-2002 20-02-2001 21-06-1996 21-09-2000 01-04-1997
WO 9610571	A	11-04-1996	AT 209648 T AU 681310 B2 AU 3189395 A BR 9504230 A CA 2200959 A1 CN 1168672 A ,B CZ 9700947 A3 DE 69524241 D1 DE 69524241 T2 DK 783503 T3 EP 0783503 A1 ES 2166830 T3 FI 971310 A HR 950507 A1 HU 77354 A2	15-12-2001 21-08-1997 26-04-1996 06-08-1996 11-04-1996 24-12-1997 15-07-1998 10-01-2002 13-06-2002 11-02-2002 16-07-1997 01-05-2002 27-03-1997 31-08-1997 30-03-1998

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 30 6163

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EPO file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-08-2002

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9610571	A	WO	9610571 A1	11-04-1996
		IL	115384 A	28-10-1999
		JP	9511527 T	18-11-1997
		JP	3287574 B2	04-06-2002
		KR	244848 B1	02-03-2000
		NO	971416 A	20-05-1997
		NZ	290936 A	26-01-1998
		PL	319636 A1	18-08-1997
		PT	783503 T	28-03-2002
		RU	2163239 C2	20-02-2001
		SI	9520096 A	30-04-1998
		SK	32597 A3	09-09-1998
		TR	960273 A2	21-06-1996
		TW	406081 B	21-09-2000
		US	5852031 A	22-12-1998
		ZA	9508223 A	01-04-1997
WO 9604250	A	15-02-1996	AU	703431 B2
			AU	2351095 A
			BR	9503572 A
			CA	2196769 A1
			EP	0775118 A1
			FI	970469 A
			WO	9604250 A1
			JP	3004727 B2
			JP	9510706 T
			NZ	284851 A
			TR	960450 A2
			NO	970498 A
WO 9534555	A	21-12-1995	AT	206708 T
			CA	2192975 A1
			DE	69523155 D1
			DE	69523155 T2
			DK	765320 T3
			EP	0765320 A1
			ES	2163506 T3
			FI	965021 A
			WO	9534555 A1
			JP	2860604 B2
			JP	9506637 T
			PT	765320 T
WO 9625414	A	22-08-1996	AU	4859596 A
			EP	0809642 A1
			JP	11500123 T

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 01 30 6163

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
 The members are as contained in the European Patent Office EDP file on
 The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-08-2002

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9625414	A		WO US	9625414 A1 5912246 A	22-08-1996 15-06-1999
WO 9808835	A	05-03-1998	AU EP HR WO JP JP ZA	3632297 A 0925291 A1 970455 A1 9808835 A1 2000502360 T 3152941 B2 9707597 A	19-03-1998 30-06-1999 31-08-1998 05-03-1998 29-02-2000 03-04-2001 25-02-1999
EP 1074257	A	07-02-2001	US AU EP HU JP NZ	6231833 B1 4897600 A 1074257 A1 0003118 A2 2001064178 A 506154 A	15-05-2001 08-02-2001 07-02-2001 28-04-2001 13-03-2001 01-03-2002
WO 0076981	A	21-12-2000	AU WO	5877500 A 0076981 A1	02-01-2001 21-12-2000